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SUMMARY
SUMMARY
Organ transplantation is now an accepted method of 
treating end stage kidney failure. Other organs are 
also being transplanted and an increasing number of 
heart, liver, pancreas and bone marrow transplants are 
being carried out. Grafts may be unsuccessful for many 
reasons but the biggest problem is graft rejection e.g. 
only approximately 40% of all first cadaver kidney 
grafts are functioning after six years.
The first prolonged human cadaver renal allograft 
survival was reported from Boston in 1962, when a 
patient was treated with azathioprine, a purine analogue 
similar to 6-mercaptopurine, to prevent rejection.
Since then, major advances in the understanding of the 
immune system, and the establislment of tissue typing 
laboratories have taken place. However, since the 
1970s graft survival figures have not improved 
significantly. Indeed, azathioprine in combination 
with corticosteroids have remained unchallenged as the 
mainstay of immunosuppressive therapy during the past 
two decades.
Recently, the discovery of Cyclosporin A has raised 
.hopes that a major advance in immunosuppression has 
been achieved. In 1976 at the Biological and Medical 
Research Division of Sandoz Limited, Basle, 
Switzerland, during a screening programme of fungus
I;
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extracts, a cyclic endecapeptide, Cyclosporin A (CyA), 
was identified as having marked immunosuppressive 
properties. This observation led to studies of CyA in 
different species with a variety of organ transplants, 
notably at Cambridge, England, Following these 
,experiments a pilot human study was begun by Professor 
Caine in Cambridge using CyA in clinical organ 
grafting, initially as the sole immunosuppressant. The 
results were encouraging,
CyA had been shown to be a potent immunosuppressant yet 
its mode of action was unclear. Early workers had 
suggested that it acted primarily on lymphocytes, 
possibly on T lymphocytes. Further information has 
revealed that the mode of action may be mediated through 
a subpopulation of T cells, namely suppressor cells.
Using the cardiac allograft model in the rat, the aim 
of the study described in this thesis was to investigate 
the mechanisms by which CyA mediated its immuno­
suppressive activity,
(LEW X BN)F^ and (LEW x WF)F^ animals were used as 
organ donors and LEW animals as recipients. CyA was 
administered at 15 mg/kg/day for 7 days commencing 
immediately after transplantation. All grafts 
functioned normally for more than 100 days in healthy 
recipients. The humoral arm of the immune response of 
these grafted and CyA-treated recipients was assessed
by examining complement-dependent cytotoxicity, 
antibody-dependent cell-mediated cytotoxicity and the 
reverse haemolytic plaque assay. The cell-mediated 
component was measured by examining lymphocyte-mediated 
cytotoxicity. Both the cell-mediated and the humoral 
components were profoundly suppressed throughout the 
100 day period after transplantation. The nature of 
this unresponsiveness was examined in more detail by 
adoptively transferring thymocytes from CyA-treated 
animals bearing well-functioning grafts into 
unmodified animals and performing test heart grafts 
24 hours later. Prolongation of these test heart 
grafts suggested that these transferred cells had 
suppressor characteristics. The failure of these cells 
to prolong third party test grafts suggested antigen- 
specific immunosuppression„ Such donor-specific 
immunosuppression was supported in vitro by the 
results obtained in the mixed lymphocyte response in 
which there was significant suppression against donor 
cells but not third party cells. In both these in 
vivo and in vitro experiments the donor-specific 
suppressor activity appeared only after the cessation 
of CyA treatment.
The finding of cells with suppressor characteristics 
is supported by the results of studies of dynamic 
responses of certain lymphoid tissues to the cardiac 
allografts. Previous studies have suggested that T 
lymphocytes in bone marrow migrate first to the thymic
æmedulla and then to the splenic peri-arterial sheath 
(PAS) Via the marginal zone (MZ). A second line of T 
lymphocytes may migrate first to thymic cortex and 
then to the splenic red pulp (RP). In these present 
experiments medu].lary thymocytes and T lymphocytes 
in the splenic PAS and MZ were strikingly reduced in 
size 1 to 2 weeks after the completion of CyA 
treatment. It has been postulated that helper and 
cytotoxic T lymphocytes may develop in the thymic 
medulla while suppressor T lymphocytes may originate 
in the thymic cortex. Thus CyA may be predicted to 
favour preferentially suppressor cell function. In 
the present experimental studies using the cardiac 
allograft in the rat it has been demonstrated that CyA 
is indeed a potent immunosuppressant, suppressing both 
cell-mediated and humoral immunity. It has also been 
shown that following the cessation of CyA treatment 
there is emergence of cells with antigen-specific 
suppressor characteristics. It is suspected that 
these suppressor cells act by abrogating or overriding 
the function of allospecific helper T cells necessary 
for initiating differentiation of cytotoxic T 
lymphocytes and antibody-producing B cells.
C H A P T E R  1
THE DEVELOPMENT OF IMMUNOSUPPRESSION
IN ORGAN TRANSPLANTATION
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THE DEVELOPMENT OF IMMUNOSUPPRESSION
IN ORGAN TRANSPLANTATION
1. Historical Aspects
The concept that deficient or diseased tissues or organs 
might be replaced by transplants from another individual 
has existed since antiquity. In Greek mythology, the 
Chimera, a mythical monster containing parts of many 
species who dwelt in Lycia, was the terror of the 
neighbourhood until she was killed by Bellerophon mounted 
on his winged steed Pegasus. The creature is described 
thus in the Iliad, VI, 180:
Organ transplantation is an increasingly used method of 
treatment. By far the organ most often transplanted is 
the kidney and renal transplant ation is now the treatment 
of choice for most patients with end stage renal failure. 
Heart, lung, liver and bone marrow transplantations are 
now being carried out with some success. More recently 
vascularised pancreatic allograft transplantations have 
been performed, also with some degree of success. In all 
types of organ transplantation the host response to the 
transplant has been the commonest.cause of failure.
Even today after twenty years’ experience in clinical 
transplantation rejection of the graft remains the single 
most important problem to be overcome.
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"A mingled monster of no mortal kind,
Behind, a dragon's fiery tail was spread 
A goat's rough body bore a lion's head,
Her pitchy nostrils flaky flames expire,
Her gaping throat emits infernal fire,"
The first generally cited legend of allografting* dates 
from the third century A,D. when twin brother surgeons 
St« Cosmas and St, Damian were alleged to have 
transplanted the whole leg of a dead Ethiopian Moor to 
a Caucasian man whose leg had been removed for tumour 
(Artelt, 1907), Perhaps the credulous public were 
unaware that the transplanted leg may have been black 
by reason of gangrene. Little was written thereafter 
until John Hunter's work, where he transplanted the 
spur of a cock to its comb, a human tooth to a cock's 
comb and a cock's testis to a hen (Hunter, 1771, 1778; 
Irvine, 1771), Not long afterwards Baronio of Italy
* Allograft (= allotransplant/homograft):
transplantation of an organ or tissues from one 
person or animal to another of the same species. 
Autograft (= autotransplant): transplant at ion
performed within the same individual i,e , as in 
transferring skin from one site to another. 
Syngeneic transplant: transplantation between two
animals of the same inbred strain i.e. genetically 
identical animals.
demonstrated that full thickness skin grafts, both in 
humans and in experimental animals, persisted 
indefinitely, while allografts sloughed in a few days 
(Baronio, 1804).
The modern era of whole organ transplantation might be 
said to have begun with the work of the ambitious French 
emigre. Carrel, and Guthrie at the beginning of the 
present century. This work was carried out initially 
in the Hull Physiological Laboratory of the University 
of Chicago and later at the Rockefeller Institute in 
New York City (Carrel, 1902). In brief, these workers, 
using dogs, were able to transplant kidneys and other 
organs and to achieve survival of autografts but not 
allografts, which were rejected by a process which was 
not then understood. Carrel recognised that the immune 
response of the recipient required modification to render 
the recipient tolerant of the organ allograft, but his 
talented mind was diverted to the study of tissue 
culture methods, which he continued from 1906 onwards.
Hektoen in 1916 first tried to modify the immune response 
in rabbits. He injected sheep blood cells intra- 
peritoneally and reported reduced production of 
antibodies by the use of organic substances such as 
benzene. However, it was not until 1952 that Baker 
attempted to apply this to experimental renal 
transplantation when he used nitrogen mustard to reduce
antibody production in the animal recipient. The 
results were not. encouraging. This is not surprising 
as very little was known of the biology of organ 
allograft rejection.
During the 1950s Dempster and Simonsen showed that 
canine kidneys grafted between individuals of the same 
species who were not identical twins were invariably 
destroyed or rejected. Between the years 1951 - 1953 
Hume performed a small number of cadaver kidney 
transplants in the human (Hume et al, 1955). In some 
of these patients the function of the transplants 
enabled the patient to live for a limited length of 
time and. one patient survived for six months. Some 
attempts were made to prolong the survival of these 
grafts by giving the recipients ACTH or steroids but 
inadequate doses were used.
In the 1950s ways were continually being sought to 
manipulate the immune response so that the body would 
accept foreign protein. Two important advances were 
made. First, Dillingham, Brent and Medawar in 1953 
demonstrated that if an animal still in utero or newly 
born was injected with foreign cells from another animal, 
it remained tolerant of that material throughout its 
life and would accept an allograft as if it were its 
own tissue provided that the graft was taken from the 
same inbred strain of animal as the cells that had been
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originally injected. This ".actively acquired immuno­
logical tolerance" of foreign cells was a demonstration 
that the immune response could be manipulated, though, 
obviously, when performed in this way it was unlikely 
to be of any practical clinical use. This finding, 
however, gave encouragement and confidence to 
clinicians that human allograft rejection might be 
avoided.
Then, in 1959, Schwartz and Dameshek in Boston reported 
that they were able to produce 'drug induced immuno­
logical tolerance'p Rabbits given the antimetabolite 
6-mercaptopurine (6-MP) no longer produced antibodies 
when injected with human serum albumin. Indeed, in the 
following year they confirmed the importance of this 
observation by demonstrating prolonged skin allograft 
survival in rabbits treated with 6-MP (Schwartz et al, 
1960). It is now known that the findings of Schwartz 
et al were not tolerance but a chemical suppression of 
part of the immune response. The demonstration of'drug 
induced immunological tolerance' to foreign tissue in an 
animal opened up the opportunity to perform successful 
organ allografts in clinical practice. Caine in London 
recognised this and very soon had demonstrated prolonged 
renal allograft survival in dogs maintained post- 
operatively on 6-MP (Caine, 1960). This observation 
was also reported by Zukoski and colleagues in 1961. 
Caine then moved to Boston, where these experiments were
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extended and Burroughs Wellcome provided derivatives 
of 6-MP for study, in particular, azathioprine, a purine 
analogue similar to 6-MP,
The first prolonged human cadaver renal allograft 
survival was reported from Boston in 1962, when a patient 
was treated with azathioprine. This case has been 
described in detail by F, D, Moore (Moore, 1964a). From 
1962 onwards, successful renal allografts were reported 
from many centres using donor kidneys obtained from 
cadavers and giving the recipients azathioprine (or 6-MP) 
for post-operative immunosuppression.
About this time Dr. Willard Goodwin (1962) in Los Angeles 
had shown a beneficial effect of steroids in a patient 
with a renal allograft who had been treated with 
cyclophosphamideo Since azathioprine was more effective 
and less toxic than cyclophosphamide in animal 
experiments it was decided to embark on a programme of 
renal allografting in man using azathioprine as the basic 
immunosuppressive drug and to add steroids if rejection 
was not controlled (Murray et al, 1963). Since then 
azathioprine in combination with corticosteroids has 
become the mainstay of post-operative immunosuppression 
after renal transplantation. The reason why azathioprine 
is used in preference to 6-MP has never been made clear. 
No trials were carried out in man to compare the two 
drugs and the often repeated statement that azathioprine
is superior to 6-MP is not based on evidence that bears 
critical examination (Berenbaum, 1971). It is of great 
interest that azathioprine and steroids have not yet 
been replaced in clinical practice, at a time when so 
many advances have been made in the immunology of 
rejection„
2. Recent Developments
During’ the last two decades attempts have been made to 
discover other techniques for suppressing the immune 
response of the recipient. During this time new 
information has been obtained about the rejection 
process and it can be anticipated that this greater 
knowledge will lead to improvements in the techniques 
of immune suppression and tolerance.
Aspects of Transplantation Biology
When an allograft is transplanted the body recognises it 
as foreign and attempts to eliminate it by the process of 
rejection. The -initial response to the organ graft is 
mounted by the recipient lymphatic tissue. A very 
simplejscheme for organ rejection is shown in Fig. 1.1. 
The allograft is detected by the immune reacting tissue 
(the ‘afferent' arc) and, as a result, lymphocytes 
become activated and a response develops which causes 
rejection of the transplant. The response may be
FIGURE 1.1
Rejection Schema of a Renal Transplant
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On transplantation of a kidney, donor antigens are 
recognised by the recipient lymphatic tissue as 
'foreign' - the afferent arc. A response is mounted 
by! the recipient lymphatic tissue against the 
transplant - the.efferent arc. The response may be 
either cell-mediated by T lymphocytes, or antibody- 
mediated by B lymphocytes (see text).
,1
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cellular or humoral or a combination, of both (the 
‘efferent* arc) but in either case the response is 
mediated by lymphocytes.
The cells involved in the cellular component of the 
immune response are under the influence of the thymus 
and these lymphocytes are referred to as thymus- 
dependent or T cells. When exposed to an allograft 
■they proliferate, A number of T cell populations are 
described. Some are responsible for destroying the 
graft (cytotoxic cells), some are directed against the 
transplant (so-called helper cells because they "help" 
the immune response) and some protect the graft 
(suppressor cells).
The humoral response to an allograft is mediated through 
the B lymphocytes, which produce antibody to the graft. 
Experimental work in animals, for instance, by Good and 
his colleagues in Minnesota (Cooper et al, 1966) showed 
that the development of lymphocytes concerned with 
antibody production was dependent on the Bursa of 
Fabricius, No .such structure has been found in humans 
but the term B lymphocyte (i,e, bursa-dependent 
lymphocyte) has become widely used for those lymphocytes 
which ure found especially in the lymphoid follicles of 
lymph nodes that produce antibody in response to 
stimulation by antigen. The B lymphocytes proliferate 
to produce the plasma cell which produces the antibody.
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The humoral antibody, which is. circulating in the blood 
stream, modifies or destroys the allogeneic graft cells. 
It is also now recognised that B cell activity is 
dependent on T cell function.
Within these two broad mechanisms several types of 
rejection are recognised clinically:
a) Hyperacute rejection: This occurs when the
recipient is presensitized to the donor tissues, for 
instance ABO blood group incompatibility. Or it can 
occur as a result of blood transfusions which enable 
the recipient to become sensitized to donor antigens 
and develop circulating cytotoxic antibodies to the 
donor tissue. This is primarily an antibody- 
mediated response and may be apparent within minutes 
of connecting the grafted organ to the recipient. 
Histological examination of the transplanted kidney 
shows sludging of the red cells and microthrombi 
formation, particularly in the glomeruli.
b) Acute rejection: This is either a cellular or
humoral response. Early acute rejection, classically 
seen at 7 to 10 days after transplantation, is 
primarily a T lymphocyte response, the kidney 
showing a dense cellular infiltration with damage 
and rupture of the peritubular capillaries. Usually 
this type of response is seen in recipients not on
immunosuppression!. When acute rejection of renal
■ i
transplants occurs, azathioprine and a corticosteroid
are normally being given, and then it is primarily 
a humoral, or antibody, response, at about 14 days 
after transplantation. Antibody binds to the walls 
of the glomerular capillaries. Usually in acute 
rejection different areas of the kidney will show 
varying histology suggestive of both a cell-mediated 
and humoral response,
c ) Late rejection: This occurs usually months or years 
after transplantation. Histology shows a sub- 
endothelial deposition of immunoglobulin and 
complement within the kidney vessels. This 
"vascular rejection", as it is sometimes called, 
can occur acutely or more insidiously over months 
or years. These changes are indistinguishable from 
those of malignant hypertension, and in less acute 
vascular rejection there may also be intimai 
proliferation in the arteries, leading to narrowing 
or obliteration of the lumen. These vascular 
changes result in renal ischaemia and failure, and 
are very difficult to reverse by immunotherapy.
This simple view of T and B lymphocytes responding to a 
transplant and initiating rejection has given way to 
mechanisms with much more complex pathways. Antibodies 
may be directed against the transplant, for instance 
cytotoxic antibodies - and yet others may protect the 
graft: - the blocking, or enhancing, antibodies. Some 
antibodies seem to prime transplant tissue cells by
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coating them, and thus make them more susceptible to 
attack by lymphocytes - this mechanism is termed 
antibody-dependent cell-mediated cytotoxicity.
In addition, increasing information is being obtained 
about ill-defined substances which were initially 
thought to be released by lymphocytes coming into 
contact with an antigen. Originally the name 
'lymphokines* had been introduced to describe this 
group of non-antibody lymphocyte factors. More 
recently, the term 'interleukin' has been used to 
describe this group of peptide hormones. Two of this 
group of hormones are Interleukin 1 and Interleukin 2.
In brief, they are involved in T cell activation and the 
essential features are as follows: Interleukin 1 (IL^) 
is produced by macrophages on encountering the antigen. 
IL^ acts on a subpopulation of T helper cells along 
with the antigen to evoke the production and release 
of Interleukin 2 (ILg). This in turn acts on antigen- 
primed T helper cells and causes mitogenesis of these 
cells. Helper cells enhance the activity of cytotoxic 
cells and B cell antibody production directed against 
the antigen. This is further discussed on page 138.
Immune Suppression
Since the rejection of tissue or organ allografts is 
the culmination of interconnected cellular and humoral
in
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events mediated by various lymphoid cell subgroups, 
agents or procedures acting directly against lymphoid 
tissue have been studied in the search for more 
efficient immunosuppression. Most of the techniques 
affect lymphocyte populations indiscriminately.
1. Agents and Procedures Affecting Predominantly 
Lymphoid Tissue
a ) Whole Body Irradiation
Isolated successes were reported in kidney grafts 
between non-identical twins using total body 
X-irradiation to the recipient (Murray et al, 1960: 
Hamburger et al, 1962), The results overall were not 
encouraging due to a high incidence of sepsis in the 
irradiated recipients,
b ) Thymectomy and Splenectomy
Starzl first advocated pre-transplant splenectomy in 
1963 to reduce.lymphoid mass and perhaps thereby to
I fattenuate rejection, A few years later Zuhlke (1967) 
and his associates observed that splenectomy and 
thymectomy in man significantly reduced the titres of 
iljgM immunoglobulin after renal transplantation. Yet 
the role of splenectomy and thymectomy is uncertain. 
Although pre-transplant splenectomy is routinely 
practised by a few transplant surgeons, since 1970 most
irk- ____
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have used splenectomy only for patients with pre- or 
post-transplant neutropaenia in an effort to improve 
azathioprine tolerance. Thymectomy is rarely performed 
in modern clinical practice.
G ) Lymph Drainage Through a Thoracic Duct Fistula
The rationale for such an approach was provided by the 
investigations in rats of Gowaris and his associates 
(Gowans, 1959; McGregor and Gowans, 1963). These 
workers demonstrated that the primary immune response 
to tetanus toxoid or sheep erythrocytes is severely 
depressed or abolished in animals whose lymphocyte 
population had been depleted by thoracic duct drainage. 
Drainage of lymphocytes by cannulation of the thoracic 
duct in humans was first tried in 1963 in St. Louis by 
Newton and later in Stockholm by Franksson (1967). A 
more recent review of the procedure in forty renal 
transplant recipients was given by Starzl in 1979. 
Despite some optimism the technique has not gained 
universal acceptance and is used only in a few centres.
d ) Antilymphocyte and Antithymocyte Globulin
These agents are derived from the sera of animals 
injected with lymphocytes or thymocytes from another 
species. In the early 1960s Woodruff reported that: i
antilymphocyte globulin, administered intraperitoneally,I :provided a major prolongation of skin allograft survival
34
in rodents. Unfortunately, the responses of the animals 
to injections of lymphocytes or thymocytes varies and it 
has been difficult to obtain preparations with standard 
biological effects. In addition, patients may develop a 
hypersensitivity to the injected animal protein. These 
globulins were first used in clinical transplantation in 
1967 but controlled trials were not carried out until 
years later. During this time the results have varied 
but have been encouraging from only a few centres.
e ) Total Lymphoid Irradiation
Total body irradiation has been administered as an 
immunosuppressive technique. Recently high dosage 
partially-selective lymphoid irradiation similar to 
that used in the treatment of Hodgkin's disease has 
been reported to be relatively non-toxic and permit 
long acceptance of experimental bone marrow, skin and 
organ allografts (Slavin et al, 1979). A few centres 
have begun to use lymphoid irradiation for preparing 
certain patients.for kidney transplantation. The 
largest experience has been obtained in Minnesota and 
although the early results appear promising (Najarian 
et. al, 1981) longer follow-up will be required before 
its usefulness can be properly evaluated.
_________________  ' . J
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2. Chemical Immune Suppression
Other investigators have studied agents with a general 
antiproliferative action. These agents, most of which 
are used as anti-cancer drugs, have a general cytotoxic 
action and render cells incapable of division. They 
include :
Ant irnet aboli tes
These compounds interfere with protein synthesis by 
competing for and blocking specific receptors. They 
include the purine antagonists 6-MP and azathioprine, 
the pyrimidine antagonist 5~fluouracil, and the folic 
acid antagonist methotrexate. Since these agents are 
only effective against proliferating cells, they are 
most effective when given after, rather than before, 
the exposure to antigen.
Azathioprine is a similar compound to 6-MP but with 
an imidazole group attached to a sulphur atom. It is 
rapidly converted back to 6-MP following ingestion and 
for this reason the activity of the two compounds is 
largely the same. As has been mentioned previously, 
the!optimum time for administering these drugs is after 
exposure to antigen and it has been shown that antibody
I
production in man is very little affected if they are 
given before (Herschet al, 1966).
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A l kylatin g Ag e uts
These compounds possess an alkyl radical with active end 
groups, usually chlorine atoms, which can bind to two or 
more different molecules. With most alkylating agents 
DNA synthesis is inhibited to a greater extent than RNA 
synthesis. Although alkylating agents have been shown 
to be most useful in treating malignancies, they have 
been of little value on the whole as immunosuppressants. 
They include cyclophosphamide, mitomycin C, nitrogen 
mustard and sulpha mustard.
Cyclophosphamide interferes with the reproduction of 
immunologically competent cells and it is more effective 
in depressing antibody response in animals if given 24 to 
48 hours after immunisation (Frisch and Davies, 1965). 
However, resting cells can also be damaged and small 
lymphocytes can be killed by a process unrelated to cell 
proliferation. In 1971 Starzl proposed that cyclophos­
phamide might be substituted for azathioprine with 
advantage in cadaveric renal and hepatic transplantation 
(Starzl et al, 1971). Patient follow-up was only 
two or three months, however, and there was no 
comparable control group. Toxicity (leucopaenia, 
thrombocytopaenia, haemorrhagic cystitis, testicular 
atrophy, nausea and vomiting) has probably been the 
reason why the drug has not been widely used in other 
transplant centres. Its main use has been in the
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treatment of malignant disease rather than in 
transplantation.
Mitomycin C has also been used. This anti-cancer drug
has been reported to enhance the immunosuppressant
activity of 6-MP (Kenis et al, 1964), but the dose 
required has rendered it unsuitable as an immuno­
suppressive agent due to severe leucopaenia and 
thrombocytopaenia.
Other Methods of Prolonging Survival of an Organ 
Transplant
Immune suppression is imperfect and therefore attempts 
have been made to reduce the immune response mounted 
against the donor organ. The methods used include:
a) Tissue typing
b) Donor pre-treatment
c) Blood transfusion.
a) Tissue Typing
Autografts do not reject and allografts between 
identical twins do not reject. Grafts between syngeneic 
animals do not reject. Therefore, could the rejection 
response be diminished if a close match between donor 
and recipient was achieved?
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The first work.was performed in mice (Gorer, 1937).
A red blood cell antigen was identified, matching for 
which had a major effect on survival of tumour 
transplants. When the growth of a transplantable 
tumour was observed in inbred mice and in hybrid 
generations, it was found that the tumour would only 
grow in mice carrying certain genes which were also 
present in the stock of origin of the tumour. From 
this work, in 1948, Snell termed the antigens 
relevant for transplantation the 'histocompatibility 
antigens'. With the development of knowledge 
concerning histocompatibility or antigens in the 
mouse there was a search for similar antigens in 
humans. Gradually evidence accumulated that there 
was a system in man based on leucocytes. Van Rood, 
and Payne, working independently, demonstrated that 
leucocyte agglutinins were produced by foetal-maternal 
stimulation. Using these sera, Van Rood (1962) 
identified a two allele* system which he called 
'group 4'„ Payne described a similar but independent 
system of antigens and as more antigens became 
identified it became clear that there were two systems
* Allele : genes forming a pair which may be alike,
Ihoniozygous, or dissimilar, heterozygous - situatedI
at a specific locus, or site, on one pair of 
chromosomes.
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of serologically-determined antigens controlled by a 
set of alleles at two closely linked loci. This was 
initially known as the L,A. system (Leucocyte; A for 
the first locus), which is located on the short arm of 
chromosome 6. These antigens are now termed the 
H.L.A.-A and the H.L.A.-B antigens. A further locus 
H pL.Ao“C has also been described. Antigens of the
H.L.A.-A, B and C series are all serologically- 
determined using antisera of known specificity. A 
fuller account of these antigens is given by Bodmer, 
W.P. (1978).
Recently a further series of antigens has been 
described - the H.L.A.-D series (1975, Report of the 
Sixth International Histocompatibility Workshop).
These antigens are defined by the way in which the 
lymphocytes respond to other lymphocytes of known 
type. Thus, typing for these antigens is based on the 
mixed lymphocyte reaction and not serological testing. 
More recently, a new serologically-determined series 
of antigens has been identified (1977, Report of the 
Seventh International Histocompatibility Workshop). 
This series is very closely related to the lymphocyte- 
determined H.L.A.-D and has become known as the 
H,LcAo-DR (i.e. D~related). A schematic demonstration 
of the H.L.A. system is given in Fig. 1.2.
FIGURE 1.2
Schematic Representation of the H.L.A. System
in the Short Arm of Chromosome 6
centromere
HLA
A C B D dr
At least 5 loci are known to belong to the H.L.A. 
system, their designation (ordered from centromere) 
is DR, D, B, C, A.
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The H.L.A. system is genetically coded, the genes being 
located on the surfaces of leucocytes, platelets, tissue 
cells and reticulocytes but are not demonstrable on 
mature erythrocytes. Each person has two antigens for 
each locus i.e. H.L.A,-A antigens, etc., and in clinical 
practice it is the antigens of the H.L.A.-A and B series 
that are typed routinely, H.L.A.-C and H.L.A.-D are not 
usually studied but increasingly H.L.A.-DR typing is 
also performed.
Clinical Relevance of H.L.A.' in Transplantation
As,details of the H.L.A, system have been discovered, 
natipnal and international organ sharing schemes have
■ ■
emerged to allow organ sharing on a "matched basis". 
Because of the rapidly increasing knowledge of these 
antigens it is hardly surprising that their role in 
clinical renal transplantation has been the subject 
of intense debate. Morris, Batchelor and Festenstein 
(1978) reviewed the role of in transplantation
and their paper may be summarised:
i) Matching for three or four H.L.A,-A and B
antigens improves the clinical results by 10 to 
30% over H.L.A.-A and B mismatches, 
ii) Matching for H.L.A.-C is probably of no benefit, 
iii) H.L.A.-D and DR matching is still being evaluated. 
Matching for H.L.A.-DR probably improves the 
prospects for renal graft survival.
Despite early optimism, the use of tissue typing and 
donor recipient matching has been only partially 
successful in improving graft survival. There are 
problems of the accuracy of typing and data collection 
in large series. Transplant registers do show that 
matching helps, although a few questions remain 
unanswered. What antigens are important? Which can 
be disregarded and which have yet to be discovered?
b ) Dohor P'r e- treatmen t, -
Attempts have been made to improve graft survival by 
treating the donor organ to reduce its antigenicity.
■-1- . ;
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Graft irradiation in vitro or pre-treatment of the 
donor with cytotoxic drugs before kidney retrieval 
have been the two main techniques used, Guttman and 
colleagues in 1969, after experimenting with many 
cytotoxic agents, found that high doses of 
cyclophosphamide and methyl prednisolone given to donor 
animals five hours before removal of a kidney, gave the 
best results. Accordingly, they used such a regime 
to treat human brain dead kidney donors (Guttman et al,
1975), The results were encouraging. However, at the 
present time the value of donor pre-treatment in 
cadaveric renal transplantation remains indoubt and is 
not widely used in clinical practice,
c) Blood Transfusion
It is now well established that the survival rate of 
renal allografts is higher in patients who have received 
than in those who have not received blood transfusions 
prior to transplantation. This observation was first 
made by Opelz in 1973, who found that patients who do 
not develop antibodies have an excellent prognosis 
following grafting. The first confirmation in Europe 
of the benefit of pre-transplant blood transfusion was 
made in Newcastle upon Tyne (Murray et al, 1974),
Results from further work in Newcastle showed that the 
development of cytotoxic antibodies is no disadvantage 
provided a donor can be found with whom the recipient
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has a negative cross-match. The presence of cytotoxic 
antibodies may delay transplantation but perhaps of 
more importance is the fact that their function and 
discovery may prevent a patient being transplanted with 
a kidney which will subsequently be uncontrollably 
rejected.
The factors responsible for the favourable influence of 
blood transfusion on renal allograft survival have not 
yet been identified. While the immunological effects 
of transfusion may be directed towards the impairment 
of cellular immune competence (Shenton et al,.1974), 
attention has been turned to the possible significance 
of lymphocyte-suppressing factors which emerge following 
blood transfusion (Shenton et al, 1979). It may be that 
more than one mechanism is responsible for the 
improvement of graft survival in transfused patients, 
including specific immunosuppression, graft selection 
and patient selection (Fabre et al, 1978).
Most centres will now deliberately give blood to 
patients who have never been previously transfused and 
who are on dialysis awaiting grafting. However, there 
is still controversy about the type of blood transfused, 
the optimal amount to give and the timing of the 
transfusion.
Regarding the type of blood transfused, some reports
indicate that the results of transplantation are better 
in patients transfused with frozen blood rather than in 
those transfused with other preparations (Polesky et al, 
1977); other reports indicate that whole blood is better 
than frozen blood (Opelz and Terasaki, 1974), while 
another report shows a similar beneficial effect no 
matter whether whole or frozen blood is used (Briggs et 
al, 1978).
One report shows that even a single transfusion places 
the recipient in a more favourable category for graft 
survival (Persijn et al, 1977). Some show no difference 
in relationship to the number of transfusions 
(Festenstein et al, 1976) and others show that the more 
transfusions that have been received the higher the 
likelihood of prolonged graft survival (Perkins and 
Salvatierra, 1977). One centre reports that 
transfusions on the day of transplantation are associated 
with improved graft survival rates (Stiller et al, 1978) 
but other analyses do not confirm this (Salaman, 1978: 
Jeffrey et al, 1978).
Despite all these developments from the earliest days of 
kidney transplantation, rejection remains the most 
important cause of graft loss. Tissue matching and organ 
sharing schemes have improved results a little and 
deliberate transfusion policies have helped a lot. 
-Azathioprine and corticosteroids remain the most widely
used drugs in human transplantation but these drugs have 
important side-effects and rejection may still occur 
when they are used. Steroids are associated with 
Cushingoid appearance, fluid retention, adrenal 
suppression, acne, psychosis, avascular necrosis of bone 
and gastro-intestinal bleeding. Azathioprine may cause 
profound leucopaenia which predisposes to widespread 
sepsis and sometimes death. The considerable problem of 
graft rejection remains. For instance, in the United 
Kingdom during the five year period 1977 to 1982 the 
survival of first cadaveric renal allografts at twelve 
months was 64%. Approximately 40% of all cadaver kidney 
grafts are functioning after six years: 60% are 
unsuccessful, the majority as a result of rejection.
Referring to azathioprine and corticosteroids nearly 
twenty years ago, Moore said "other drugs are being used 
to some extent; better drugs will be discovered and 
other chemical methods are certain to be effective" 
(Moore, 1964b). As yet the ideal immunosuppressant 
has not been found but the aim remains to find such a 
method which would not harm the donor organ or the 
recipient and which would prevent any rejection episodes 
being mounted against the graft. Such an ideal 
immunosuppressive agent should be easily obtainable at 
a reasonable cost, totally palatable and without side-
effects for the patient. Recently the discovery of
!
Cyclosporin A has raised hopes that such a drug has been
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found
)orin A
In 1976 at the Biological and Medical Research Division 
of Sandoz Limited, Basle, Switzerland, during a screening 
programme of fungus extracts, Borel and colleagues noted 
that "metabolites of the species Cylindrocarpon Lucidum 
Booth were found to depress antibody production in mice". 
Further investigations led to the isolation of the active 
principle, a cyclic peptide consisting of 11 amino acids 
with a molecular weight of 1,202.6, to which the name of 
Cyclosporin A (CyA) and experimental designation of 
pL-27-400 were given (Fig. 1.3). The compound, which is 
also found in cultures of Trichoderrna polyspo,rum (Link Ex 
Pers) Rifai, was a novel antilymphocytic agent containing 
1 amino acid which had never previously been isolated or 
known in free form. Supplied as a white powder, the non­
steroidal peptide is insoluble in water although it can 
be dissolved in alcohol or a fat emulsion (Petcher et al,
1976). It can be administered either orally or 
parenterally.
In 1976 Borel demonstrated that CyA depressed immune 
reactions both in vivo and in vitro and prolonged skin 
graft survival in mice. This observation led to studies 
of CyA in different species with a variety of organ 
transplants, notably at Cambridge, England. The
FIGURE 1.3
Cyclosporin A
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Cyclosporin A (OL-27-400) is a metabolite derived from 
two species of fungi: Cylindrocarpon Lucidum Booth and 
Trichoderrna polysporum (Link Ex Pers) Rifai. Its 
molecular weight and formula are 1202,6 and
^62^^111^11^12' ^espeetively, It is a ring peptide 
consisting of 11 amino acids. The white powder is 
not water soluble.
rejection of heterotopic heart grafts in rats was delayed 
by CyA (Kostakis et al, 1977), CyA was more effective 
than azathioprine in prolonging canine renal grafts 
(Caine and White,- 1977), orthotopic cardiac allografts 
in pigs (Caine et al, 1978a), renal allografts in rabbits 
(Green and Allison, 1978) and canine pancreatic grafts 
(McMaster et al, 1980).
Following these experiments a pilot human study was begun 
using CyA in clinical organ grafting initially as the 
sole immunosuppressant (Caine et al, 1978b). This study 
involved 50 patients receiving 56 cadaveric organ 
allografts, 45 kidneys, 6 pancreases and 5 livers. The 
results were encouraging and numerous other clinical 
investigations have subsequently been initiated in an 
attempt to identify such features as the ideal dosage,
timing and duration of treatment and the side-effects
of the drugs. Other studies were designed to investigate 
the pharmacodynamics of the drug. In spite of very 
active programmes of research there is yet much to be 
discovered about Cyclosporin A and particularly about its 
mode of action fn a biological system.
Aims of the Studies 
The aims of the studies described in this thesis were as
■follows;
(1) To investigate CyA as an immunosuppressive agent in
the rat cardiac allograft model.
(2) To study both the humoral and cellular arms of the
host immune response when treated with CyA.
(3^ ) To discover whether donor-specific suppressor cells
appear in recipient rats during or after treatment 
with CyA. i
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■ MATERIALS AND METHODS
The Animal Model 
1, General Considerations
The experimental models in general use in organ trans­
plantation research are either renal allografts in dogs 
or rats, where rejection of the kidney can be determined 
by the blood creatinine exceeding a chosen level, or 
cardiac allografts in rats, where rejection can be 
determined by the time when the transplanted heart 
ceases to beat.
It is very difficult to obtain the necessary numbers of 
inbred large animals e.g. dogs and therefore rats and 
mice were considered as suitable experimental animals.
It is not easy to perform organ allografts in mice and 
it is technically easier to transplant the rat heart 
than the kidney. Therefore the model selected was that 
of the rat heterotopic cardiac allograft.
This rat heart model has several advantages. First, 
hearts grafted between inbred strains of rats that 
differ in major histocompatibility are rejected at an 
uniform and predictable time ( 6 - 8  days after 
transplantation). Second, this rejection process can 
be accurately monitored in individual hosts by 
palpation of the transplant through the abdominal wall.
Third, unlike renal allografts, the rejection of cardiac 
allografts is not preceded or accompanied by any major 
physiological abnormalities in the host, such as uraemia, 
that may alter immune responses. Fourth, rejection of 
the heterotopic cardiac allograft does not result in 
death of the recipient animal so that post-rejection 
recovery of the lymphoid organs can be studied in the 
recipient.
2 o Choosing the Rat Strains
In selecting rats for the study the following 
requirements had to be met:
a) The rats must be of different histocompatibility 
groupings to ensure they are allogeneic.
b) All rats must be inbred and be readily obtainable 
from reliable commercial resources.
c) They must share the same red cell antigens i.e. 
they must have the same blood groupings.
d) They must be adult male rats weighing between 150 
' and 300 g (a weak sex antigen has been described
in rats (Heslop, 1973) and therefore rats of one 
sex only were used; male rats were used as they 
are larger age for age than female rats).
e) They should be hardy and resistant to infection,
(rats are very susceptible to respiratory viral 
infections, which could interfere with 
immunological experiments) and be able to withstand 
surgical operations.
.■Si
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f) The donor-recipient pairing should provide a model of 
rejection that is reliable and consistent with 
minimal variation of the time taken to reject the 
graft.
The following donor-recipient combinations fulfilled 
these criteria:
Heart donors - (Lewis x Brown Norway)F^ Hybrids
- (Lewis X Wistar Furth)F^ Hybrids 
Heart recipients - (Lewis)
For many years in the Surgical Research Laboratory at 
the Harvard Medical School this combination of F^ hybrid 
donor animals had been used in cardiac allograft 
experiments. Accordingly, there was a plentiful supply 
of these animals. This combination had been used in 
many earlier studies of immunological manipulation of 
the rejection process (Tilney et al, 1978: Hendry et al, 
1979). The rats chosen are classified as follows, where 
AgB or H-1 is the histocompatibility type determined 
serologically and AgC is the red cell antigen.
RAT AgB H-1 AgC
LEW 1 1 1 2
(LEW X BN)F^ 3 n 2
(LEW X WF)F. 4 w 2
The History of Each Rat
LEW. (LEWIS) ORIGIN: LEWIS to APTEKMAN and BOGDEN, 1954
at 20 generations; to SILVERS, 1958 at 31 
generations. 70+ generations. Albino appearance.
WE (WISTAR/FURTH) ORIGIN: J. FURTH, 1945 from Wistar
Institute Stock. 30+ generations. Albino 
appearance.
BN (BROWN NORWAY) ORIGIN: SILVERS and GILLINGHAM,
1958, from a brown mutation maintained by H. D. KING 
and Pc APTEKMAN, 40+ generations. Brown, non­
agouti appearance.
3. Technique of Heterotopic Cardiac Allografting in 
Rats
The technique of heart transplantation is well 
described in the literature (One and Lindsey, 1969).
Essentially heterotopic cardiac allografting involves 
transplanting the donor heart to the abdomen of the 
recipient, the donor animal being sacrificed. The 
donor aorta is anastomosed to the recipient abdominal 
aorta and the donor pulmonary artery to the inferior 
vena cava of the recipient. The donor superior and 
inferior vena cavae are ligated, as also are the 
pulmonary veins. Blood flow to the transplanted heart
is through the donor aorta in retrograde fashion and 
thus into the coronary circulation to perfuse the 
myocardium with oxygenated blood. The blood collects 
in the coronary venous system and enters the right 
atrium and then the right ventricle from which it 
passes, via the pulmonary artery, to the inferior vena 
cava of the recipient. The myocardium is perfused and 
therefore the heart beats, though it is not functioning 
as a normal cardiac pump.
Whilst it is possible to use rats between 150 and 350 g 
in weight in this experimental model (below this weight 
the vessels are very small, and above it considerable 
fat deposition makes the transplant operation more 
difficult), it was desired to maintain uniformity 
throughout the studies as far as possible and therefore 
rats weighing 220 to 250 g were normally used.
Absence of a palpable beat, combined with an inability 
to record any electrical activity in the transplanted 
heart, was taken as clinical evidence of rejection.
The technique of EGG recording is described later in 
this chapter.
(i) Anaesthesia
General anaesthesia was always used. Rats are somewhat 
unpredictable in their response to general anaesthesia 
and a number of drugs were tried. The best anaesthetic
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was a combination of ether and a low dose barbiturate.
Induction was performed with ether by placing the rat 
in a large covered glass flask that contained an ether- 
soaked cottonwool base. After about 20 to 30 seconds 
the rat became unconscious, and it then received an 
injection of pentobarbitone sodium intra-peritoneally,
The dose of pentobarbitone was 30 mg/kg body weight.
Anaesthesia was maintained with ether administered from 
a pad of cottonwool contained in a small cone. At all 
times the aim was to keep the anaesthesia as ’’light" 
as possible to facilitate rapid recovery at the end of 
the operation.
(ii) Instruments
The vascular anastomoses are of vessels approximately
1.5 mm in diameter and therefore microsurgical 
instruments and an operating microscope were used. The 
microscope was a binocular Carl Zeiss operating 
microscope, bench mounted, and with foot controls to 
control focussing and magnification. A magnification 
of approximately 6x was ideal.
Beverage can 'pull tops' attached to elastic bands were 
ideal abdominal wall retractors during the implantation 
of the heart. Fine pointed forceps were required for 
handling the small vessels and jewellers' forceps. No. 5,
were used. A pair of Castroviejo iris scissors and a 
straight Castroviejo needle holder, the jaws of which 
were ground to a smaller size to suit this particular 
procedure, completed a small and uncomplicated set of 
instruments. It is essential when doing microsurgery 
to keep the instruments as simple as possible.
(iii) The Operation
(a) Donor (Fig. 2.1)
After the donor rat has been anaesthetised the abdomen 
is opened and 50 units of heparin injected 
intravenously through the inferior vena cava. The 
anterior chest wall is separated from the diaphragm and 
the anterior rib cage is divided with scissors on both 
sides of the sternum from lower rib margins to 
clavicles, A ligature (1) is placed around the 
superior vena cava and another around the inferior vena 
cava (2). One blade of the angled Castroviejo scissors 
is placed in the transverse sinus and the aorta and 
pulmonary artery are divided as far from the heart as 
possible to give as much length to these vessels which 
facilitates the anastomosis. The superior and 
inferior venae cavae are divided distal to the 
ligature. Pulmonary veins are ligated "en masse",
divided: and the heart removed. Once out of the body,
ithe heart is immediately placed in a N/saline bath at 
4^C. Then it is removed and irrigated with N/saline at
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FIGURE 2.1
Removal of the Donor Heart
A ligature (1) is placed around the superior vena cava 
and another around the inferior vena cava (2). One 
blade of the Castroviejo scissors is placed in the 
transverse sinus.
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4°C, first through the aorta and then the pulmonary 
artery. The irrigation cools the heart, removes blood 
clot and by filling the ventricles prevents air 
embolism after the transplant,
(b) Recipient (Fig, 2 ,2 )
Once the aorta (A) and the inferior vena cava (IVC) are 
adequately cleaned, and all branches and tributaries 
tied over a 1,5 cm length, a black silk sling (S) is 
placed around the aorta proximally (to control the 
aorta at the end of the operation when the clamps are 
released) and two small rubber guarded bulldog clamps 
are applied to the aorta and inferior vena cava, A 
longitudinal incision of 2,5 to 3 mm is made in the 
aorta (using a No, 11 scalpel blade) and the aorta is 
flushed free of blood and blood clot with saline using 
a 20 gauge flexible catheter,
(c) Transplantation
The aortic anastomosis is performed by starting at the 
rostral end, running a continuous suture (8/0 
monofilament polyamide, Ethicon 8170) along the left 
side of the anastomosis and tying the suture at the 
caudal end of the anastomosis. The heart is then 
turned over to the left side of the rat's abdominal 
cavity and using the same suture, the other side of 
the anastomosis is completed. The inferior vena cava
'
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FIGURE 2.2
Preparation of the Recipient
The aorta (A) and the inferior vena cava (IVC) are 
cleaned. A black sling (S) is placed around the aorta
 ^ Iproximally. Rubber-guarded bulldog clamps are placed 
across the aorta and inferior vena cava.
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is opened longitudinally and blood and blood clot 
syringed out with normal saline. As with the aorta, 
sutures are placed at the end of the venotomy, and the 
pulmonary artery secured at each end to the inferior 
vena cava. The medial anastomosis is performed first 
using the rostrally placed suture. This has to be 
performed from within the vessel lumen. A continuous 
suture is used and, on reaching the caudal end of the 
incision, the suture is placed outside the vessel and 
is ligated to the stay suture at that end. Finally, 
the lateral side of the anastomosis is completed and 
the abdomen closed.
Using the light anaesthesia described earlier, the rats 
were normally conscious and walking around their cage 
thirty minutes after completion of the operation.
Typical times recorded for the operation were:
a) Initial warm ischaemic time (i.e. the
time taken to remove the heart from
the chest and place in cold saline) 3 minutes
b) Cold saline storage of heart 5 minutes
c) Anastomosis time 15-18 minutes
4. Post-operative Problems
Very few were encountered. A small number of rats died 
after the operation without recovery and without 
obvious cause of death. Two rats developed paraplegia
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and were sacrificed as soon as this was noticed. A 
small number of transplanted rats* hearts stopped 
beating within 24 to 48 hours. These were invariably 
infarcted and these rats were excluded from any study. 
Once the technique was mastered, the success rate in 
transplantation was over 95%.
5. Post-operative Monitoring
(a) The Heart
In the early days after transplantation simple digital 
palpation of the transplanted heart was sufficient to 
prove that the graft was functioning. When the heart­
beat became difficult to palpate, EGG recordings were 
used. These were easily performed. The animals were 
given a light ether anaesthetic and then two electrodes 
were placed one on each side of the transplant, and the 
third, indifferent electrode was placed on the right 
thigh. Needle electrodes were used. The recording 
given was of the transplanted heart.
To record the rat's own heartbeat - which was always 
done to differentiate between transplant and native 
hearts - the electrodes on each side of the 
transplanted heart were placed to the right and to the 
left forelimbs respectively and a further recording 
taken.
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When electrical activity from the transplanted heart was 
no longer recordable, a laparotomy was performed to 
ensure that the heart was not beating, and the heart 
was then removed for histological examination (to 
confirm rejection) and the animal was sacrificed.
An example of the EGG tracings obtained from the rat's 
own heart, and from the transplanted heart, at periods 
following transplantation until just before the 
cessation of the heartbeat are shown in Fig. 2.3.
(b) Blood Analyses
After transplantation, and during the period of 
rejection, several blood parameters were measured in 
recipient rats. The most suitable method for 
obtaining blood samples was as follows. Under a light 
anaesthetic, a small incision was made over the 
clavicle. The jugular vein and the upper part of the 
pectoralis major was exposed. Venepuncture was 
performed by introducing the needle to the vein 
through the peetoralis major muscle. This prevented 
subsequent bleeding when the needle was withdrawn.
1 ml samples were obtained and the wound was closed 
with black silk sutures. The total length of time for 
the procedure was 2 to 3 minutes. No rat was bled more 
than once if a transplant had been given and each 
experimental group of rats contained animals that were 
not bled to control any possible immunosuppressive
FIGURE 2.3
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EVC.G. Recordings of the Rat's Own 
Heart and the Transplanted Heart
HETEROTOPIC C AR D iAC  A L LO G R A F T  -  CONTROL GROUP
Native heart
TranSijlaiUeci heart -  2 days post transplant
Transpiatited heart -  A  days post transplant
Transplanted heart -  6 ilays post transplant. Heartbeat not jniljjahle.
Transplanted h e a r t 7 days post transplant
The change in the electrical activity of the 
transplanted heart during the 7 days after 
transplantation is shown.
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effects of the trauma of venepuncture.
6 . Cyclosporin A
Cyclosporin A, supplied by Sandoz Limited, Basle, 
Switzerland, was dissolved in olive oil at 70^C by 
constant stirring for 30 minutes and administered for 
7 days (15 mg/kg/day) by intramuscular injection 
beginning immediately after transplantation. Earlier 
studies in rats had shown that cardiac allografts could 
be maintained by an intramuscular dose of 15 mg/kg/day 
without toxic effects (White et al, 1980). Ryffel and 
colleagues described both hepatotoxicity and 
nephrotoxicity in rats receiving 45 mg/kg/day for 13 
weeks and indeed a mortality rate of 30% was recorded 
in their study (1983).
Measurement of the Immune Response
In the past monitoring of B cell activity has been 
much more thoroughly studied than T cell activity, 
mainly because, the product, antibody, could be so 
easily collected and characterised. However, the 
other arm of the immune response, T cell function, is 
equally important, although several features make it 
more difficult to study. In particular, T cells have 
diverse functions (e.g. cytotoxic cells, suppressor 
cells, helper cells) and the nature of their antigen- 
specific receptors has proved difficult to demonstrate
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Until the 1960s the most commonly used methods of 
measuring the immune response of a host involved the 
staining of antigen-bearing cells with dye. These 
antigen cells were incubated with serum or cells of 
the host. A strong host immune response would result 
in lysis of a large number of these cells. The number 
of intact cells following incubation was visually 
counted, thus measuring the humoral or cellular 
activity of the host. However, these techniques have 
associated pitfalls. Engelfriet and Britten (1966) 
have pointed out the problem of variable staining 
depending on dye concentration and the time of 
incubation with the dye. Some cells are only faintly 
stained and may not be counted. Furthermore, Walford 
et al (1965) have observed that stained cells enlarge 
and fragment with time, resulting in an underestimation 
of the percentage of cell damage.
These difficulties can be obviated by using radio­
isotope techniques and studying not the cell but the 
supernatant radio-activity. The technique of 
labelling antigen cells with a radio-isotope was 
originally described by Goodman in 1961 studying mouse 
tumour cells. Radio-isotope release studies eliminate 
some sources of variability inherent in any technique 
which involves visually counting cells. The 
following tests of immune responsiveness were applied 
in our studies.
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Measurement of Humoral Activity
a) Complement-dependent cytotoxicity
Historically, complement activity was recognised by 
Bordet (1895), who showed that the lytic activity 
against red cells of freshly obtained rabbit anti-sheep 
erythrocyte serum was lost on ageing or heating to 56^C 
for half an hour but could be restored by the addition 
of fresh serum from an unimmunised rabbit. It is now 
known that heating serum to 56°C for half an hour 
inactivates complement.
The serum of normal animals of many species contains a 
group of at least eleven protein factors making up what 
is called the "complement system". This series of 
substances‘is activated by complexes of antigen with 
certain kinds of antibody. Combination of antigen and 
antibody leads to a structural change in the antibody 
molecule, a change which is recognised by one of the 
components of complement. A cascade reactions begins, 
activation of one member of the chain leading to the 
activation of many more of the next line. The end 
result is that the activity of one of the final 
activated components of complement "punches" a 
microscopic hole in the plasma membrane of the antigen 
cell (Fig. 2c4).
By labelling the antigen cell with radio-isotope the
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FIGURE 2.4
COMPLEMENT DEPENDENT C YTO TO XIC ITY
Antigen-antil jody complexûs
Cell lysis%
Antigen-Antibody complexes in the presence of 
complement results in lysis of the antigen cell. By 
labelling the antigen cell with radio-isotope the 
amount of antibody present can be measured.
tuiiount of antibody can bo assessed by measuring the 
quantity of radio-isotope released.
Labelling of Cells
Antigen cells were Brown Norway thymocytes labelled 
51with Cr as described by Sanderson (1964). The thymus 
was disrupted with fine forceps in Roswell Park Memorial 
Institute (RPMl) 1640 and then filtered through 
cottonwool to remove debris. Cells were prepared by
washing' twice in RPMI 1640, staining with trypan
blue and counting using a light microscope.
1 X 10^ cells in 0.2 ml of RPMl 1640 were
incubated with 400 |aC of sodium chromate
n(Nag CrO) for 90 minutes at 37 C. Following 
incubation the cells were washed twice with 
RPMI 1640 to reduce excess isotope and diluted 
to the desired concentrations.
Serum
Sera from grafted and untreated animals and 
animals grafted and CyA-treated were collected 
at varying intervals (5, 7, 14, 21, 50 and 
100 days) after transplantation. Dilutions 
of 1:10 to 1 :10,000 were tested in volumes 
of 25 jiL for complement-dependent 
cytotoxicity.
Assay
Serial dilutions of test sera (25 pL) were 
51incubated with Cr-labelled Brown Norway
4thymocytes (1 x 10 in 25 pL) for 60 minutes 
50 }-iL of rabbit complement (1:10 dilution) 
were added to the target cells and serum in 
microtitre plates and incubated at 22^C in 5'
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carbon dioxide* for 90 minutes. After incubation 
150 pL of RPMI 1640 was added to the plates, which 
were then centrifuged at 2,000 revolutions per minute 
(rpm) for 10 minutes.
Using an automatic pipette 100 of the supernatant
was removed and by counting in a îf counter for 1 minute
51the specific release of Cr was measured.
Spontaneous Lysis and "Freeze Thaw"
Spontaneous lysis (i.e. cell lysis which would occur in 
the presence of cells, medium and complement without 
test sera) was determined by substituting test sera 
with tissue culture medium. The assay was carried out 
as above.
In order to determine the possible total release of 
51■ Cr, medium was substituted for serum in three wells 
of the microtitre plates. Prior to centrifugation the
* Carbon Dioxide: Both oxygen and carbon dioxide are
probably essential for cell survival. Apart from 
its requirements in tissue metabolism, the bicarbonate 
ion is the most important buffering ion in most 
culture media and most systems require control of 
the carbon dioxide tension in the gas phase and in 
the medium.
h;::
mixture was alternately frozen and thawed using dry ice 
and acetone and water at 37°C. This procedure causes 
lysis of all cells and release of all the incorporated
51cr.
Percent Lysis
% Lysis =
51Experimental Cr Release (using test sera)_________ SpontaneousLysis
Freeze thaw lysis SpontaneousLysis
X 100
b) Antibody-dependent cell-mediated cytotoxicity
When a host is exposed to an antigen e.g. allograft cell, 
antibodies will be produced and antigen-antibody 
complexes formed. Combination with antibody will 
encourage the death of the allograft cell by promoting 
contact with phagocytes or by activation of the 
complement system producing direct membrane damage. A 
quite distinct cytotoxic mechanism was suggested by 
Perlraann and Perlmann in 1970. These workers 
described a class of host cells, known as K cells 
("killer cells"), which could also attach to the 
antibody. These K cells are morphologically similar to 
small or medium size lymphocytes although without easily 
demonstrable immunoglobulin on their surface and are not 
phagocytic. After attachment, this K cell-antibody- 
complex can directly destroy the antigen cells i.e. the 
cells of the allograft. In other systems K cell activity
can be demonstrated against tumour cells or cells 
infected with micro-organisms. By labelling the 
antigen cell with radio-isotope, the amount of 
antibody can be assessed by measuring (die liberated 
radio-activity (F ig. 2.5).
FIGURE 2.5
ANTiBODY DEPEDENT CELL MEDIATED CYTOTOXICITY
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Antigen-Antibody complexes in the presence of K cells 
results in lysis of the antigen cells. By labelling 
the antigen cell with radio-isotope, the amount of 
antibody can be readily assessed.
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Target (Antigen) Cells
Brown Norway thymocytes were prepared by washing in
RPMI 1640, staining with trypan blue and counting with
a light microscope, 1 x 10^ cells in 0,2 ml RPMI 1640
51were incubated with 400 pC of Na^ CrO for 90 minutes 
at 37°C, Following incubation the cells were washed 
twice with RPMI 1640 to remove excess isotope and 
diluted to the desired concentration.
Serum
Sera from grafted untreated animals, and animals grafted 
and CyA-treated were collected at varying intervals 
(5, 7, 14, 21, 50 and 100 days) after transplantation. 
Dilutions of 1:10 to 1:10,000 were tested in volumes of 
0.01 mlp
Effector Cells (containing K cells)
Splenocytes from unmodified LEW rats were used. The 
spleen was disrupted by gentle blunt dissection and 
the cells washed with RPMI 1640, stained with trypan 
blue and counted with a light microscope.
Assay
0,01 ml of serial dilutions of LEW anti-LBN sera was
4 51incubated with 0,5 ml of 1 x 10 Cr-labelled Brown
Norway thymocytes for 30 minutes at 37^C in 5% CO .
0,1 ml effector cells in a ratio of 100:1 were added
and the mixture was further incubated for another 3|
hours at 37°C in 5% CO^. Following the incubation the
microtitre plates were spun at 2,000 rpm for 10 minutes
at 4°C. Using an automatic pipette 100 pL of the
supernatant was removed and by counting in a X" counter
51for 1 minute the specific release of Cr was measured.
'"1;
Spontaneous Lysis and "Freeze Thaw"
This technique was similar to that used in the 
complement-dependent cytotoxicity assay (Page 70) 
substituting medium for test sera in the above assay
Percent Lysis
% Lysis
Experimental (test sera)
51Cr Release SpontaneousLysis
Freeze thaw lysis SpontaneousLysis
X 100
c ) Reverse Haemolytic Plaque Assay
The haemolytic plaque assay, first described by Jerne 
and Nordin in 1963, detected single cells which 
secreted immunoglobulin M (IgM) binding to surface 
determinants on red cells. Since then modifications 
have been made and the assay described below is based 
on that of Gronowicz and colleagues described in 1976
This assay makes use of the fact that protein A produced 
by Staphylococcus Aureus binds to the portion of the 
antibody IgG molecule (Gustafson et al, 1967). Sheep 
red blood cells (SRBC) are coated with Staphylococcal 
Protein A and, in the presence of complement and IgG, 
lysis of the SRBC*s will occur.
By assessing the amount of red cell lysis which occurs 
then it is possible to measure the number of antibody- 
producing cells (in this study; splenocytes). (Fig. 2.6)
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Coupling of Protein A to Sheep Red Cells
Protein A was coupled to sheep red cells with chromium 
chloride (CrCl^) after the technique of Vyas and 
colleagues (1968). 0.1 ml of protein A (0.5 mg/ml) was
mixed with 1 ml of CrCl^ (2.5 x 10~^M) and 0.1 ml of 
packed, washed sheep red cells. All reagents were in 
0.9% sodium chloride (NaCl). The mixture was incubated 
for 1 hour at 30^C. The red cells thereafter were 
washed once in 0.9% NaCl and twice in balanced salt 
solution o
Assay
The Staphylococcal Protein A red blood cells (20 pL 
SRBC) were mixed with 2 x lo"^  splenocytes, from LEW 
recipients of (LEW x BN)F^ cardiac grafts, and guinea
FIGURE '2.6
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HAEMO LYTIC  PLAQUE ASSAY
RucI
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Immunoglobulin 
secreting cell
Red
blood
cell
Complement
Staphyloccal 
protein A
Lysis
Protein A produced by Staphylococcus Aureus binds to 
IgG. Sheep red blood cells are coated with 
Staphylococcal Protein A and, in the presence of 
complement and IgG, lysis will occur.
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pig complement at 1:20 dilution in balanced salt
solution. This mixture was warmed to 44^C prior to the
addition of 150 pL of 50% Agarose and spread onto 5 cm
Petri dishes. Following a 15 hour incubation at 37°C
in 5% COg, complement-mediated lysis of SRBC produced
clear zones of plaques around each individual antibody-
secreting cell. These plaque-forming cells were
visualised by direct light and their number expressed 
6per 10 splenocytes.
Measurement of Cell-mediated Activity
a) Lymphocyte-mediated Cytotoxicity
Govaerts, in 1960, first showed in vitro that living 
lymphocytes from renal grafted animals produced 
specific cytotoxic lesions in ‘renal cultures from the 
corresponding donors. Since then numerous assays 
measuring the amount of lysis caused by direct contact 
of host lymphocytes (^effector cells’) and antigen 
(‘target cells’) have been described. Cells acting as 
target cells must be easily recognisable as foreign by 
the host lymphocytes i.e, they must have numerous 
‘antigenic sites’ on their surface. Those cells 
commonly used in lymphocyte-mediated cytotoxicity 
assays are peripheral blood cells and splenocytes. In 
the rodent peripheral blood lymphocytes have as many 
surface antigenic sites as thymocytes (Terasaki and 
McClelland, 1963) and hence both are effective. The
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preparation of spleen cells is not easy since it is 
difficult to separate splenocytes from erythrocytes. 
Thymocytes were chosen in these studies because of 
their ease of preparation, their known high density 
of histocompatibility antigenic sites and their 
susceptibility to lysis under the conditions used 
(Hendry et al, 1979), The original assay was 
described by Vainio and colleagues in 1964, By 
labelling the donor strain cells with radio-isotope 
and measuring its release the level of cytotoxicity 
or "cellular immunity" in the host can be measured 
(Fig, 2,7), The following assay is based on that of 
Brunner and colleagues described in 1968,
Effector Cells
The attacking cell or effector cell population, from 
CyA-treated and untreated animals, were harvested at 
intervals (3, 7, 14, 21 and 100 days) after 
transplantation. These cells were recipient 
splenocytes or cells infiltrating the cardiac 
allografts. The cells infiltrating the cardiac 
allografts were, in the main, an heterogenous 
population of mononuclear cells, including 
macrophages and T and B lymphocytes (Tilney et al, 
1975),
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FIGURE 2.7
LYMPHOCYTE MEDIATED CYTOTOXICITY
Antigen (allograft) cell
Sensitized host 
lymphocytes
Cell lysis
Antigen cells are lysed by direct contact with host 
lymphocytes. Radio-isotope release from antigen cells 
is a measure of the ’’cellular immunity" »
Target Cells
Donor strain Brown Norway thymocytes labelled with ^^Cr 
(see page 6 8 ) acted as target cells.
Assay
Attacker to target cells were assayed in a ratio of
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100:1 (2 X 10^/ml:2 x 10^/ral). 100 pL target cells and
100 pL effector cells were incubated in microtitre
plates for 3| hours at 37^C in 5% CO^» After the
incubation 150 pL of RPMI 1640 was added to the plates,
which were then spun at 2,000 rpm for 10 minutes at
Using an automatic pipette 100 pL of the
supernatant was removed- and by counting in a K counter
51for 1 minute the specific release of Cr was 
measured.
Spontaneous Lysis and "Freeze Thaw"
In order to determine the spontaneous lysis of target 
cells which would occur thymocytes from unmodified 
Lewis animals were substituted for cells from grafted 
and treated animals.
51The total Cr release possible was determined by 
51adding 100 pL Cr-labelled target cells and 100 pL 
medium and alternately freezing and thawing this 
mixture, a technique which lyses all the cells causing 
release of all■incorporated radio-isotope.
Percent Lysis
% Lysis
51% Cr Release in Presence of Immune Lymphoid Cells
Total Cr Incorporated (Freeze Thaw)
51 Cr Release in Presence of Normal Lymphoid Cells51Cr Release in Presence of Normal Lymphoid Cells
X 100
Harvesting of Cellular Infiltrates
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The procedures used in isolating infiltrating cells 
from cardiac allografts were modifications of 
techniques previously described by Tilney et al (1975). 
Cardiac allografts were transplanted in groups of 4 
animals and at serial intervals after grafting the 
donor hearts from each group were removed and cleaned 
of surrounding tissue and clot. Each myocardium was 
then diced in 5 ml of RPMI 1640 containing 0.005 m 
Hepes (hydroxyethylpiperazine ethane sulphonic) acid 
buffer and 4% (v/v) heat-inactivated foetal calf serum 
(inactivated by heating at 56°C for 30 minutes) with
0.1 ml of 0.2% EDTA (sodium ethylene diaminetetracetic 
acid). The tissue was then expressed through 60 gauge 
stainless steel mesh and filtered through cottonwool 
to remove remaining debris. The suspension of 
infiltrating cells was centrifuged twice at 200 g for 
15 minutes, washed in RPMI 1640 and incubated for 20 
minutes in 5% CO^ at 25°C, then 20 minutes at 37^C in 
10 ml of buffered RPMI 1640 containing 0.4 mg of 
deoxyribonuclease per ml. The cell suspension was then 
washed with culture medium, resuspended and layered 
over Ficoll-Hypaque. After centrifugation at 750 g for 
15 minutes, the cells were collected from the 
interface layer, washed in RPMI 1640 and counted.
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Thymectomy and Isolation of Thymocytes
In rats under ether anaesthesia, a midline cervico- 
thoracic incision was made and the sternum split in its 
upper third. The thymus was exposed, gently teased 
away from surrounding tissues and removed intact. 
Parathymie lymphnodes were always excluded from thymic 
tissue. The thymus was mechanically disrupted in RPMI. 
1640 with fine forceps and filtered through cottonwool 
to remove debris. The resultant suspension of 
thymocytes could then be stained with trypan blue and 
counted using a light microscope.
Statistics
Statistical significance was determined by the use of 
Student's two-tailed t-test. All graphs of results 
indicate the mean result and the standard error of the 
mean result.
83
C H A P T E R  3
RESULTS OF GRAFT SURVIVAL AND OF THE
MEASUREMENT OF THE IMMUNE RESPONSE
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RESULTS OF GRAFT SURVIVAL AND OF THE
MEASUREMENT OF THE IMMUNE RESPONSE
1. Graft Survival in Untreated Recipients
I
If
Cardiac allografts were performed in two groups of rats, 
seven animals in each group. (LEW x BN)F^ and 
(LEW X WF)F^ were used as donors, LEW animals being the 
recipients. No immunosuppressive agent was given.
Results
Cardiac Allograft Survival in Unmodified Recipients
When (LEW x BN)F^ animals were used as donors the 
mean survival time standard deviation (MST + SD) 
was 7 + 2  days and using (LEW x WF)F., 6 + 1  day. 
These results are shown in Table 3.1.
2, Graft Survival in Recipients Treated with 
Cyclosporin A
The same combination of donor-recipient pairs was 
used. In all experiments LEW rats were the 
recipients. In 14 allografts (LEW x WF)F^ rats were 
the heart donors and in a second group of 14 
allografts (LEW x BN)F^ were used as donors 
(Fig. 3.1).
Table 3.1
Survival of Cardiac Allografts in Unmodified Recipients
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Survival No. in Times MST + SDRecipient Group (days) (days)Donor
(LEW X BN)E_ LEW 5,6,6,6, 7 + 2
7,8,11
(LEW X WF)F, LEW 5,5,5,6 , 
6,7,9
6 + 1
The mean survival time standard deviation using 
(LEW X BN)F^ animals as donors was 7 _+ 2 days and using 
(LEW X WF)F^ animals, 6 + ^ 1  day.
Recipient rats received intramuscular CyA (15 mg/kg'/day) 
for 7 days only commencing immediately after 
transplantation. During this time the animals were not 
used for any other experimental procedures which could 
alter the allograft survival time e.g. repeated 
anaesthesia for blood sampling may in itself be 
immunosuppr ossi ve (IIurnp 11roy e t al, 1969).
FIGURE 3.1
Cardiac Allografts in CyA-treated Recipient Rats
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C y A  f o r  7 d a y s  
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The survival of all cardiac allografts was prolonged 
in recipients treated with CyA (15 mg/kg/day).
■ . ■. . V.,,- ^ , .
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Results
Allograft Survival in Recipients Treated with 
Cyclosporin A
When recipient rats were treated with Cyclosporin A all 
grafts survived more than 100 days when both donor 
groups were used (Table 3.2).
It has therefore been clearly shown that in this donor- 
recipient combination Cyclosporin A significantly 
prolongs cardiac allograft survival.
Measurement of Humoral and Cell-mediated Activity in 
Untreated and Cyclosporin A-treated Grafted Animals
In all the following studies (LEW x BN)F^ animals 
acted as organ donors and LEW animals recipients.
The following studies were made;
Measurement of Humoral Activity
a) Complementrdependent cytotoxicity
b) Antibody-dependent cell-mediated cytotoxicity
c) Reverse haemolytic plaque assay
Measurement of Cell-mediated Activity 
a) Lymphocyte-mediated cytotoxicity
Table 3.2
Survival of Cardiac Allografts 
in Cyclosporin A Treated Recipients
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i
Donor Recipient No, in Group Survival Times
(LEW X BN)F^ LEW 14 Each animal Z> 100
days
(LEW X WF)F^ LEW 14 Each animalZ> 100
days
Using both (LEW x BN)F^ and (LEW x WF)F^ animals as 
donors, all cardiac allografts survived over 100 days
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3. Humoral Activity
a) Complement-dependent cytotoxicity
24 LEW rats received cardiac allografts from (LEW x BN)F^ 
donors and were given no immune suppression. Blood was 
taken from four animals at each of 5, 7, 10, 14, 17 and 
21 days after transplantation and tested for complement- 
dependent cytotoxicity.
24 LEW rats received cardiac allografts from (LEW x BN)F^ 
donors and the recipient rats were treated with Cyclo­
sporin A intramuscularly 15 mg/kg/day for 7 days. Blood 
samples were taken from recipient rats in groups of four 
at days 3, 7, 14, 21, 50 and 100 after transplantation 
and studied for complement-dependent cytotoxicity. No 
rat was used on more than one occasion for this study.
Results
Unmodified LEW recipients of (LEW x BN)F^ cardiac allo­
grafts showed a rise in titre of antibody (35% - 42%) 
about the time of acute rejection at 5 to 7 days which 
persisted for one week thereafter. Negligible complement- 
dependent cytotoxicity (<5%) was demonstrated in CyA- 
treated recipients of well-functioning grafts as long as 
100 days after transplantation (P<0,001). In this 
sensitive assay less than 20% is a negative result 
(Fig. 3.2).
FIGURE 3.2
COMPLEMENT DEPENDENT C YTO TO X IC ITY
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The lower line in the'graph shows that there is 
negligible complement-dependent cytotoxicity at all 
points studied in the 24 rats treated with CyA. In 
untreated recipients complement-dependent 
cytotoxicity rises significantly at the time of acute 
rejection and persists for 7 to 10 days thereafter.
This experiment has produced evidence that the humoral
. • /arm of the immune response is significantly diminished
in Cyclosporin A-treated recipients.
91
b) Antibody-dependent cell-mediated cytotoxicity
16 LEW rats received cardiac allografts from (LEW x BN)F^ 
donors and were given no immune suppression. Blood was 
taken from four animals at each of 5, 7, 14 and 21 days 
after transplantation and tested for antibody-dependent 
cell-mediated cytotoxicity.
24 LEW rats received cardiac allografts from (LEW x BN)F^ 
donors and the recipient rats were treated with intra­
muscular Cyclosporin A 15 mg/kg/day for 7 days* Blood 
samples were taken from these animals in groups of four 
at 5, 7, 14, 21, 50 and 100 days after transplantation 
and studied for antibody-dependent cell-mediated cyto­
toxicity. No rat was used on more than one occasion for 
this study.
Results
Antibody-dependent cell-mediated cytotoxicity peaked 
(7.5% - 8.5%) 7 days after transplantation in untreated 
allograft recipients, at the time of completed graft 
rejection. In CyA-treated graft recipients, antibody- 
dependent cell-mediated cytotoxicity did not rise above 
3.5% during the 100 days period after transplantation 
(P<0.01) (Fig. 3.3).
This experiment has produced further evidence that the 
humoral arm of the immune response is significantly 
diminished in CyA-treated recipients.
FIGURE 3.3
A N T I B O D Y  D E P E N D E N T  C E L L  M E D I A T E D  C Y T O T O X I C I T Y
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The lower line in the graph shows that there is 
negligible antibody-dependent cell-mediated 
cytotoxicity at all points studied in the 24 rats 
treated with CyA. In untreated recipients the 
antibody-dependent cell-mediated cytotoxicity rises 
significantly at the time of acute rejection and 
persists for 7 to 10 days thereafter.
c)
Protein A was coupled to sheep red blood cells as
described on page 7 5 . Normal control values for this 
assay were determined.by studying the spleen cells from 
11 LEW rats which had received no graft or treatment* 
Splenectomy was performed and the spleens were 
mechanically disrupted with fine forceps. The 
suspension obtained was filtered through cottonwool to 
remove debris and the spleen cells appeared in the 
filtrate. Trypan blue was added to the filtrate to 
mark the spleen cells, which were then counted by light 
microscopy in a counting chamber. The assay was then 
performed as described on page 75,
In a similar way spleen cells were prepared from two 
test groups of rats. The first group comprised 19 LEW 
recipients grafted with (LEW x BN)F^ hearts and given 
no immunosuppression. The spleens were removed 7 days 
after transplantation when rejection was established. 
The second group consisted of 21 LEW recipients 
grafted with (LEW x BN)F^ hearts and treated for the 
first 7 days after transplantation with Cyclosporin A 
(15 mg/kg/day) intramuscularly. On day 7 the spleen 
cells from eleven recipients were studied, on day 14 
four spleens, on day 21 four spleens and on day 100 
two spleens.
Results
In the control group there were 1500 plaques per 10 
spleen cells. In the group of rats grafted but
6
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receiving no immune suppression the number of plaques
6was greatly increased to above 6000 per 10 spleen 
cells. No increase in plaque-forming cells was 
observed in any of the rats which were grafted and 
treated with Cyclosporin A (Fig, 3,4),
Thus each of the three tests of humoral activity in 
grafted recipients has shown that CyA produces a very 
significant decrease in the humoral component of the 
immune response when compared to animals grafted and 
not given CyA,
4, Cell-mediated Activity
a) Lymphocyte-mediated cytotoxicity (spleen cells)
Target cells were prepared from the thymus of Brown 
Norway rats and labelled with ^^Cr as described on 
page 68.
Two groups each of 16 LEW recipients received cardiac 
allografts from (LEW x BN)F^ donors. The first group 
of rats received no CyA and from this group the spleens 
of four animals were studied at each time interval of 
3j, 7, 14 and 21 days after transplantation. In the 
second group the recipient rats received CyA 
(15 mg/kg/day) intramuscularly for the first 7 days 
after transplantation and the spleens of four of these 
animals were studied at each time interval of 7, 14,
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FIGURE 3.4
Plaque Formation in Control Rats and in 
Grafted Rats with and without CyA
-UL,
N“ ll
N-19
CYCLOSPORJN-A
SPLEEN
T
N -l l ZC_M-4
JXL.
N” 4
NORMAL UNTREATED DAY 7 DAY 14 DAY 2 t  DAY 100
DAY 7
In the Reverse Haemolytic Plaque Assay, numbers of 
plaque-forming cells from spleens of CyA-treated, 
grafted animals were significantly (P 0.0001) less 
than those from unmodified graft recipients throughout 
the entire follow-up period.
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21 and 100 days. The lymphocyte-mediated cytotoxicity 
was assayed as described on page 77.
Results
A strongly positive lymphocyte-mediated cytotoxicity 
result was observed in the rats grafted and not given 
CyA. In the group given CyA a modest lymphocyte- 
mediated cytotoxicity result (15% - 18%) was seen at 7 
days which was significantly less (PO.OOOl) than that 
noted in untreated animals (26% - 31%). From day 14 no 
significant lymphocyte-mediated cytotoxicity was shown 
in CyA-treated animals (Fig. 3.5).
This experiment demonstrates that CyA significantly 
reduces the lymphocyte-mediated cytotoxicity when spleen 
cells from Cyclosporin A-treated animals are used as 
effector cells acting against target cells.
b) Lymphocyte-mediated cytotoxicity (graft 
infiltrating cells)
This experiment was performed in precisely the same
\manner as the previous one except that the effector 
cells were those lymphocytes invading the grafted 
hearts. The cells infiltrating the myocardium were 
extracted and prepared as described on page 81.
In a group of 12 LEW recipients grafted with (LEW x BN)F^
FIGURE 3.5
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The upper line shows a strongly positive lymphocyte- 
mediated cytotoxicity in untreated recipients and the 
lower line shows a significantly reduced response in 
CyA-treated animals.
hearts and given no CyA, four animals were killed at
/a ay 7 , four at day 14 and four at day 21 and 'the 
infiltrates of the transplanted hearts studied.
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In a second group of 16 LEW recipients grafted with 
(LEW X BN)F^ hearts and given CyA intramuscularly 
(15 mg/kg/day) for the first 7 days after 
transplantation, four of the heart transplants were 
examined at each of day 7, 14, 21 and 100 days after 
transplantation. The lymphocyte-mediated cytotoxicity 
between the target cells and the cells from the 
infiltrate was assayed.
Results
Eig. 3.6 shows a series of results for the infiltrating 
cells similar to that already shown for splenocytes.
Therefore CyA significantly reduces the lymphocyte- 
mediated cytotoxicity when both splenocytes and graft 
infiltrating cells are used as the effector cells 
against the same target cells.
The previous group of experiments has confirmed that 
Cyclosporin A is a potent immunosuppressant in the 
rat cardiac allograft model. (LEW x BN)F^ and 
(LEW X WF)F^ cardiac allografts functioned 100 
days without rejection episodes in recipients given 
intramuscular CyA (15 mg/kg/day) for 7 days only 
commencing immediately after transplantation. The 
drug causes a profound suppression of both humoral 
and cell-mediated immunity as measured by the 
significantly diminished complement-dependent
FIGURE 3.6
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The cytotoxicity mounted by lymphocytes infiltrating the 
heart grafts of CyA-treated recipients was abolished 
(3 to 8%) when compared with the lymphocyte-mediated 
cytotoxicity mounted by infiltrating cells from 
untreated controls which ranged from 30 to 39%
{P<0.0G01) 7 days after transplantation.
«
I
cytotoxicity, antibody-dependent cell-mediated 
cytotoxicity, plaque-forming cells and lymphocyte- 
mediated cytotoxicity assays.
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DOES CYCLOSPORIN A PRODUCE 
DONOR-SPECIEIC IMMUNOSUPPRESSION?
The experiments described in the previous chapter have 
confirmed CyA to be a potent immunosuppressant using 
the cardiac allograft model in the rat. Is this 
suppression antigen-specific or could antigens from a 
third party donor be "accepted" by CyA-treated 
recipients after the administration of CyA had been 
stopped? To answer this question an attempt was made 
to demonstrate in vivo the presence of cells with 
suppressor characteristics. If present, would these 
suppressor cells be antigen-specific? In addition, the 
mixed lymphocyte response (MLR) was studied to see 
whether any in vitro specificity was present.
1. Are Suppressor Cells Present in Cyclosporin A-treated 
Recipients?
As previously mentioned in Chapter 1 , many immuno­
suppressive drugs act preferentially on dividing cells 
without any specificity and their immunosuppressive 
effects are a by-product of a general toxic effect on 
cells. The immune response of the host to the graft 
involves proliferation of lymphocytes against the graft 
and hence the highest degree of drug specificity 
possible would be for a drug to interact exclusively 
with lymphoid cells vital for graft rejection and to 
damage or destroy them.
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The various lymphocyte subpopulations, their function 
and their intricate inter-relationships occurring 
throughout the immune system are gradually becoming 
better defined. For example, Gershon and colleagues 
demonstrated that lymphocytes can have a suppressive 
effect on the immune system. These suppressor cells 
can be defined as cells, usually subpopulations of 
lymphocytes, which suppress the reactivity of other 
lymphocytes involved in graft rejection.
The aim of the following study was to demonstrate 
whether these suppressor cells are present in CyA- 
treated cardiac allograft recipients. "Cell transfer" 
experiments were performed.
Cell Transfer Studies
‘Test* heart grafts were performed between (LEW x BN)F. 
donors and LEW recipients. No pre- or post-operative 
immunosuppression was given. 24 hours before 
transplantation, these LEW recipients are injected 
intravenously with cells obtained from CyA-treated 
LEW recipients of (LEW x BN)F^ cardiac allografts. 
Prolongation of survival of these 'test' heart grafts 
would identify the transferred cells as having 
suppressor characteristics.
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Methods
Previous studies from the Surgical Research Laboratory, 
Harvard Medical School, had confirmed that both 
thymocytes and spleen cells transferred from enhanced 
recipients of cardiac allografts significantly 
increased the survival of test grafts in unmodified 
syngeneic animals (Tilney et al, 1978). Thymocytes 
produced optimal prolongation of test grafts and hence 
thymocytes were used in preference to spleen cells in 
the present cell transfer experiments. Additional 
experiments from the same laboratory, involving 
thymocyte transfer studies in rats, had identified the 
most effective "dose" of cells to be (1 x 10^) (Hendry 
et al, 1979). No dose response experiments were 
undertaken in the present study.
(LEW X BN)E^ cardiac allografts were transplanted into 
20 LEW recipients and each rat treated with 
intramuscular CyA (15 mg/kg/day) for 7 days. Four 
animals were sacrificed at each of 7, 11, 21, 50 and 
100 days. A further four (LEW x BN)E^ cardiac 
allografts were transplanted into LEW recipients which 
received no CyA. In addition, four LEW animals were 
treated with CyA (15 mg/kg/day) for 7 days without any 
associated cardiac allograft. All these LEW animals 
acted as the sources of the cells to be transferred. 
Additionally, cells were transferred from unmodified 
LEW animals i.e. LEW animals without an allograft and
•ii
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without CyA.
In each of the present series of experiments (1 x 10^) 
thymocytes, prepared as described on page 82, were 
transferred. Prior to transfer these cells were 
"trypsinised" to remove any attached CyA. Following 
trypsinisation the cells were transferred by 
intravenous injection (under light ether anaesthesia) 
into groups of 4 unmodified LEW animals. 24 hours 
after being given the cells, each of these animals 
received a (LEW x BN)F^ cardiac allograft.
Thus the sources of transferred cells were:
Group 1) Untreated, ungrafted LEW animals 
Group 2) Untreated, grafted LEW animals 
Group 3) CyA-treated, ungrafted LEW animals 
Group 4) CyA-treated, grafted LEW animals 7 days after 
transplantation 
Group 6 ) CyA-treated, grafted LEW animals 11 days 
after transplantation 
Group 6 ) CyA-treated, grafted LEW animals 21 days 
after transplantation 
Group 7) CyA-treated, grafted LEW animals 50 days 
after transplantation 
Group 8 ) CyA-treated, grafted LEW animals 100 days 
after transplantation
Each group comprised four animals.
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Trypsinisation of Transferred Thymocytes
Single suspensions were prepared from the thymus by 
disrupting the organ with fine forceps in RPMI 1640 
medium, filtering through cottonwool to remove debris 
and washing twice in RPMI 1640. The cells were then 
incubated in protein-free medium containing 10 pL of 
trypsin per ml for 30 minutes at 37°C. These cells were 
then washed three times in RPMI 1640. Under these gentle 
conditions, the majority of surface proteins are removed 
from rat thymocytes and lymphocytes (Strom et al, 1977). 
The specific purpose was to ensure the removal of all 
surface CyA.
Results
The ’test’ heart graft survival varied depending on the 
source of the transferred cells (Fig. 4.1). When cells 
had been taken from untreated and ungrafted animals, 
untreated and grafted, CyA-treated and ungrafted , CyA- 
treated and grafted and transferred 7 days after trans­
plantation, all ,16 associated test heart grafts rejected 
by 8 days. In contrast, cells transferred from LEW 
animals treated with CyA for 7 days and bearing well- 
functioning (LEW X BN)F^ heart grafts for 11, 21, 50 and 
100 days, prolonged the survival of the 16 associated 
test hearts significantly (P-<C 0.001),
These studies demonstrate that CyA-treated rats bearing
FIGURE 4,1
Cardiac AllograftSurvival after Cell Transfer
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Survival curves are noted for test (LEW x BN)F.^ cardiac 
allografts after thymocyte transfer. Four test heart 
grafts are in each group. Sources of thymocytes are 
shown.
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well-functioning, cardiac allografts develop a 
population of lymphoid cells with suppressor activity 
exerted in vivo against donor antigens. These cells 
have been shown to emerge after the cessation of CyA 
treatment. The inability of cells from CyA-treated but 
ungrafted and grafted and untreated animals to prolong 
test heart survival demonstrates that an antigenic 
stimulus as well as the effects of the drug is required 
for the development of these suppressor cells.
2, Specificity of Suppressor Effect on Test Allografts
The above experiment has demonstrated that suppressor 
cells do emerge in LEW recipients of (LEW x BN)F^ 
hearts treated with CyA for the first 7 days after 
transplantation. Are these cells antigen-specific or 
could any donor antigen be "accepted" by these host 
animals? This question could be answered by implanting 
a third party heart graft alongside the (LEW x BN)F^ 
heart after some time interval. This experimental 
technique has been carried out previously at the 
Surgical Research Laboratory (Tilney et al, 1978) 
but is both time-consuming and technically 
difficult. Alternatively, the (LEW x BN)F^ heart 
could be removed from the LEW host and replaced by a 
third party heart. In both these experimental 
situations prolongation of third party heart graft 
survival would support the presence of antigen- 
specific suppressor cells.
111 the present experiments to be described, specificity 
of these suppressor cells was examined by introducing 
a third party heart graft ( (LEW x WF)F^ hybrid) 24 
hours after cell transfer and using this as the test 
heart,
Methods
16 LEW animals were grafted, 8 animals with (LEW x BN)F^ 
cardiac allografts and 8 with (LEW x WF)F^ cardiac 
allografts. Each LEW recipient was treated with CyA 
intramuscularly (15 mg/kg/day) for 7 days, 14 days 
following transplantation these animals were 
sacrificed and (1 x 10^) thymocytes (obtained as 
described previously) were injected intravenously into 
16 unmodified LEW rats. 24 hours following cell 
transfer these 16 LEW animals were each given a heart 
graft, 8 from (LEW x BN)F^ animals and 8 from 
(LEW X WF)F animals. Thus, of the 8 (LEW x BN)F^ test 
heart grafts, 4 LEW hosts had received cells from LEW 
animals bearing well-functioning (LEW x BN)F^ grafts 
and 4 from LEW animals bearing (LEW x WF)F^ grafts. 
Similarly, of the 8 (LEW x WF)F^ test heart grafts, 4 
LEW hosts had received cells from LEW animals bearing 
well-functioning (LEW x WF)F^ grafts and 4 LEW hosts 
had received cells from LEW animals bearing well- 
functioning (LEW X BN)F^ grafts.
1
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Results
The specificity of this suppressor effect is shown in 
Fig, 4,2. The survival of test (LEW x WF)P^ allografts 
was prolonged to 13 + 2 days after transfer of (1 x 10^) 
thymocytes from CyA-treated LEW recipients of 
(LEW X WF)F^ heart grafts 14 days after 
transplantation (P = 0,002), However, no prolongation 
was noted when thymocytes from CyA-treated LEW 
recipients of (LEW x BN)F^ heart grafts were 
transferred at 14 days into unmodified LEW recipients 
of (LEW X WF)F^ test grafts (MST jF SD = 6 + 1 day). 
Similarly, (LEW x BN)F^ test grafts in LEW recipients 
survived for only 6 ^ 1  day after transfer of 
thymocytes from CyA-treated animals bearing (LEW x WF)F^ 
cardiac grafts. Hence specificity of unresponsiveness 
to the original donor strain, and not to a third party 
strain, was demonstrated.
These studies have demonstrated that CyA-treated rats 
bearing well-functioning cardiac allografts develop a 
population of lymphoid cells with specific suppressor 
activity exerted in vivo against donor antigens.
These cells have been shown to emerge after the 
cessation of CyA treatment and do not prolong graft 
survival when the graft is taken from a third party 
donor,
Could the results of these in vivo experiments be
FIGURE 4.2
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Prolongation of test cardiac allografts following 
thymocyte transfer from CyA-treated, grafted animals is 
a donor-specific phenomenon. Survival of appropriate 
test cardiac allografts is prolonged significantly 
(P - 0.002) in recipients bearing specific grafts but 
not with third party grafts.
Ill
supported by studies in vitro? Donor-specific 
suppression with CyA treatment was examined by studying 
the Mixed Lymphocyte Response (MLR).
3, Mixed Lymphocyte Response
The initial description of this assay was provided by 
Bach and Hirschhorn in 1964. Cells from two 
individuals/strains which have different surface 
antigens are mixed together in vitro. If one cell 
population recognises the other as foreign it begins 
to proliferate. This proliferation can be measured 
by the incorporation of radio-labelled precursors into 
DNA (deoxyribonucleic acid) (Bain et al, 1964).
In practice the cells are allowed to react for 4 to 5 
days and then tritiated thymidine (TdR) is added to 
the culture. If there has been any proliferation then 
TdR will be incorporated into DNA. By extracting the 
DNA and determining the amount of radio-label 
incorporated a measure of the degree of proliferation 
is obtained. Since both populations will recognise 
each other and respond by proliferating, one 
population can be treated with agents which prevent 
proliferation such as mitomycin C or X-ray so that it 
cannot proliferate but can only stimulate. This is 
called an one way MLR (Fig. 4.3).
In this study lymphocytes from donor animals or third
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FIGURE 4.3 #
'ONE-WAY' MIXED LYMPHOCYTE RESPONSE
Cell f rom grafted, . 
treated or unmodif ied 
control  animals 
(Responder cells)
X-irradiation
Cells from donor or 
third party animals 
(Stimulator cells)
Cells mixed and incubated with  Concanavaiin A
Tr i t ia ted  thymid ine incorporated 
into DNA of prol i ferat ing cells 
(Responder cells)
Determining radiolabel is measure of degree of 
prol i ferat ion
Lymphocytes from donor animals or third party animals 
(stimulator cells) are irradiated and mixed with 
lymphocytes from grafted, CyA-treated animals or 
control animals (responder cells) (see text).
:n 3
party animals (stimulator cells) were irradiated and 
mixed with lymphocytes from grafted, CyA-treated 
animals or control animals (responder cells).
The result of this assay determines whether the 
lymphoid cells of grafted, CyA-treated animals react 
equally with donor cells and with third party cells.
Methods
Donor and recipient lymphocytes were obtained from the 
thymus and submandibular or cervical lymph nodes. They 
were removed under sterile conditions. These tissues 
were disrupted with fine forceps in RPMI 1640 medium 
and filtered through cottonwool to remove debris 
before washing twice in RPMI 1640. The cells were then 
purified by differential velocity sedimentation on a 
Ficoll-Hypaque (specific gravity = 1.080) gradient, 
based on the technique described by Harris and 
Ukaejiofo (1969). This technique involves layering 
the cell suspension onto 2 ml of a Ficoll-Hypaque 
mixture. A virtually pure suspension of lymphocytes 
appears as a thin white layer immediately below the 
Ficoll-Hypaque interface. These cells are collected 
using a fine pipette and are then washed twice and 
resuspended in RPMI 1640.
Cells were obtained from the submandibular and cervical 
lymph nodes of 4 unmodified (LEW x BN)F^ rats and from
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a group of 4 unmodified third party ( (LEW x WF)F^ ) 
animals. These lymph node cells were used as the
stimulating populations in the one way MLR, and were
~ 137irradiated with 3000 rads from a C source.
5Responder lymph node or thymus cells (2 x 10 ) were 
collected from 4 control (unmodified) LEW animals and 
from groups of 4 LEW recipients of (LEW x BN)F^ 
cardiac allografts treated with CyA (15 mg/kg/day) for 
7 days and sacrificed at intervals of 7, 14, 50 and 
100 days after transplantation. These responder cells 
were mixed with an equal number of stimulator 
irradiated lymph node lymphocytes from donor animals 
( (LEW X BN)F^ ) or third party ( (LEW x WF)F^ ) animals 
in flat-bottomed microtitre plates. Three replicates 
were placed in wells of total volumes of 0.2 ml.
The cells were incubated at 37^C in 10% CO^ for 96
hours with Concanavaiin A in a concentration of
16 pg/ml. Concanavaiin A is a glycoprotein prepared
from Jack bean meal which can induce mitosis in T
lymphocytes. 6 hours before harvesting 0.02 ml of
3normal saline containing 1.0 pc of HTdR (specific 
gravity 6.7 c/mM) was added to each well. The cells 
were harvested onto fibreglass filters. The filters 
were then placed into vials and 4 ml of scintillation 
fluid was added for counting with a Beckmann beta 
counter.
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Results
The reactivity of lymph node lymphocytes and 
thymocytes from CyA-treated rats bearing well- 
functioning (LEW X BN)F^ allografts, against 
X-irradiated donor lymphocytes was significantly less 
(P <  0.0005) than the reactivity when performed against 
X-irradiated third party lymphocytes, (LEW x WF)F^ on 
days 14, 50 and 100 days following transplantation.
On day 14 the reactivity of host thymocytes against the 
third party cells increased to an unexpectedly high 
level and no explanation can be given. However, at 
day 7 when CyA was still being administered to the 
recipient animals, the reactivity of host lymph node 
lymphocytes and thymocytes was generally suppressed 
against the cells from both the specific donor and the
third party animals (Fig. 4.4).
Thus, in cardiac allografted and CyA-treated rats, the 
emergence of cells with antigen-specific suppressor 
characteristics has been demonstrated in vivo by 
thymocyte transfer experiments and these suppressor 
cells are most likely to be also responsible for the 
specificity detected in the one way MLR. It has also
been demonstrated, both in vivo and in vitro, that
these cells only appear when treatment with CyA was 
discontinued.
FIGURE 4.4
Reactivity of host lymph node lymphocytes and thymocytes 
against donor and third party lymphocytes in the MLR
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The activity of lymph node lymphocytes (LN) and 
thymocytes (Thy) from CyA-treated recipients was 
significantly (P<0.0005) less in the MLR against donor 
lymphocytes (Stimulation index <2) than against third 
party lymphocytes (Stimulation index 5-50) 14 to 100 
days after grafting. However, when CyA was still being 
administered (day 7), MLR activity was suppressed 
against both specific and third party cells 
(Stimulation index <5).
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RESPONSE OF LYMPHOID TISSUE TO CARDIAC 
ALLOGRAFTS IN RATS TREATED WITH CYCLOSPORIN A
The experiments described previously have confirmed 
that CyA is a potent immunosuppressant in the rat 
cardiac allograft model and specific suppressor cells 
are produced in the host protecting the graft against 
rejection. The following study was designed to 
determine the dynamic responses of lymphoid tissues 
(spleen and thymus) to cardiac allografts, the hosts 
having been treated with CyA. These responses may 
give further information on the mechanism of action of 
the drug.
Organ allografts in rats elicit marked systemic 
responses, including temporary splenic enlargement and 
decrease in the size of the thymus (Baldwin et al, 
1979a). In addition, it has been shown from the 
Surgical Research Laboratory, Harvard Medical School, 
that the lymphoid responses to allografts can be 
disrupted by various biological manipulations that 
increase graft. survival. These include immunological 
enhancement, transfer of cells with suppressor 
properties or depletion of T lymphocytes (Baldwin et 
al, 1979b). Would the lymphoid tissues of recipient 
rats change when they were treated with CyA?
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1. Anatomy of Rat Spleen
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The parenchyma (splenic pulp) is of two distinct types 
White pulp is typical lymphatic tissue which surrounds 
and follows the arteries. The red pulp (RP) is 
associated with numerous erythrocytes. On the cut 
surface the white pulp appears as scattered grey areas 
It forms a peri-arterial sheath (PAS) of lymphocytes 
around the arteries. Cells present within this 
tissue are predominantly small lymphocytes but in 
addition there are medium size and large lymphocytes, 
monocytes and plasma cells. Betweeen white and red 
pulp areas are poorly delineated marginal zones (MZ) 
of diffuse lymphatic tissue containing few lymphocytes 
and numerous macrophages. Areas of intense 
lymphocyte proliferation are known as germinal centres 
(GC). The positions of these compartments are shown 
in Fig. 5.1.
f
Anatomy of Rat Thymus
This organ consists of two lobes, each of which 
contains thousands of lobules, composed of cortical 
and medullary components. The cortex is densely 
populated with uniformly packed small lymphocytes 
whereas the medulla is more sparsely populated 
(Fig. 5.2).
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FIGURE 5.1
White Pulp of Normal Rat Spleen 
(A) - Diagrammatically, (B) - Histologically
a m
•i* '.A’
Arteries (shown in cross-section and partial 
longitudinal section) are surrounded by the compact small 
lymphoid cells of the PAS (black), and eccentrically 
located nodules of large lymphoid cells of the GC 
(stippled). Lymphoid cells within the macrophage 
network of the MZ (hatched) separate the PAS of larger 
arteries from the RP, but the PAS of terminal 
arterioles is in direct contact with the RP,
Figure 5.1A x50- B x40.
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FIGURE 5.2
Normal Rat Thymus
The normal thymus of a Lewis rat has a thick cortex (C) 
sharply demarcated from the medulla (M). x20
3. Materials and Methods
a) Animal Model
(LEW X BN)F^ rats were the cardiac allograft donors and
12:
LEW animals the recipients.
b) Animal Groups
(1) 18 CyA-treated LEW rats bearing (LEW x BN)F^ 
cardiac allografts were sacrificed in groups of 3 
at 3, 7, 14, 21, 50 and 100 days.
(2) 12 rats received a 7 day course of CyA but no 
graftc These animals were sacrificed in groups
of 3 at days 3, 7, 14 and 21 after the commencement 
of treatment.
(3) 12 rats received cardiac allografts but no CyA 
treatment. These were sacrificed in groups of 3 
at days 3, 7, 14 and 21 after transplantation.
c ) Cyclosporin A
CyA was administered intramuscularly to recipient rats
in a dose of 15 mg/kg/day for 7 days commencing on the
day of transplantation. No further immune suppression
was given.
d) Histological Methods
The spleen, thymus and grafts of all rats were weighed 
and thin slices were fixed in cold (4^C) acidified 
formalin (5% glacial acetic acid and 10% formalin in 
water). Paraffin sections from each specimen were 
stained with Giemsa stain and Haematoxylin and
12:
Eosin stains. The sizes of lymphoid compartments were 
qualitatively verified by planimetric measurements on 
projections of complete cross-sections through the 
thymus and spleen. These measurements were expressed 
as percentages of total cross-sectional area and 
multiplied by the weight of the individual organ in 
order to relate changes in compartment size to changes 
in organ size.
4. Results
a) Spleen
In untreated recipients marked splenomegaly occurred 
with transient increase from 0,63 g to 1.5 g in spleen 
weight. This was almost totally because of an 
expansion of the red pulp by immunoblasts and plasma 
cells (Fig. 5.3). In CyA-treated grafted animals not 
only did splenomegaly not occur during the entire 100 
day period studied but splenic weight actually 
decreased slightly (from 0.63 g at day 0 to 0.48 g at 
7 and 14 days). . This was attributable to a 50% 
decrease in the size of the peri-arterial sheath area 
and a 67% decrease in the size of the marginal zone 
area (Fig. 5.4). The peri-arterial sheath and marginal 
zone areas are heavily populated by medullary thymus- 
derived lymphocytes (Goldschneider, 1976). The sizes 
of germinal centre and red pulp areas were less 
affected. These size changes were maximal from 7 days
Spleen Weight- Untreated Recipients
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Weight changes occurring in the spleen of untreated 
(Fig. 5.3) and CyA-treated (Fig. 5.4) (LEW) recipients 
of (LEW X BN)F^ cardiac allografts are shown. Relative 
weights of the splenic compartments are also shown 
(see text).
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(when the dally CyA treatments were completed) to 21 
days, whereas by 50 days all the splenic compartments 
had returned to their normal bulk.
In the spleens of CyA-treated recipients, the PAS and 
MZ compartments populated by medullary thymus-derived 
lymphocytes decreased in size with progressive cell 
depletion a Some active germinal centres were formed 
and a moderate proliferation of large immunoblasts 
occurred in the peripheral PAS and RP at 3 days (Fig. 
5.5), However, these immunoblasts did not expand the 
RP at 3 days and did not progress on to the 
considerable proliferation of immunoblasts and plasma 
cells in the RP observed at 7 days in untreated 
allograft recipients (Fig. 5,6). Instead, the RP and 
GO areas remained inactive 7, 14 and 21 days after 
grafting. However, in the CyA-treated animals, 
splenic morphology returned to normal by 50 and 100 
days with well-demarcated cellular PAS and MZ areas 
and active germinal centres.
b ) Thymus
Total thymic weight in untreated grafted recipients 
decreased by 40% during acute rejection (from 0,40 g 
to 0.24 g at 7 days), related primarily to a decrease 
in cortical thymocytes (Fig. 5.7). In CyA-treated 
rats thymic weight diminished further within the 
first few days after transplantation (0,12 g by 3
Spleen Histology
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FIGURE 5.5
Æ
Spleen of CyA-treated (LEW) recipient of (LEW x BN)F^ 
cardiac allograft at 3 days is shown. A moderate 
proliferation of large immunoblasts (I) is noted in the 
PAS and RP, x60
Spleen Histology
FIGURE 5.6
Spleen of untreated (LEW) recipient of (LEW x BN)F^ 
cardiac allograft at 7 days is shown. Considerable 
proliferation of immunoblasts (I) in the RP is noted 
x40
vteight Changes, in Thymus of Untreated Recipients
127 :
0.4
0,3
FIGURE 5.7 0.2-ë)
0.1
   '^‘Too
Days id ter transplatualion
Weight Changes in Thymus of Cyclosporin A-treated Recipients
FIGURE 5.8
I
.o i'«u
0.4
0.3
0.2
0.1
.1 I_______L
3 7 14 21 ' 50  ' 100
Days after transplantation
Weight changes occurring in the thymus of untreated 
and CyA-treated (LEW) recipients of (LEW x BN)F^ 
cardiac allografts.
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days), only partially recovering by 50 and 100 days 
(Fig. 5.8). Although both cortical and medullary 
compartments were decreased in size in the CyA-treated 
animals the medullary compartment was totally 
eliminated in all 6 rats with (LEW x BN)E^ heart 
grafts killed at 14 and 21 days.
The most dramatic morphological changes after 
grafting and treatment with CyA occurred in the 
recipient thymus. At 3 days there was a marked increase 
in most cells in the thymic cortex (Fig. 5.9).
Although increases in most cells were noted in 
untreated allograft recipients, proliferation was, 
at the most, focal. By 7 days most medullary 
thymocytes had been eliminated in the CyA-treated rats 
and vascular stroma and histiocytes containing 
phagocytosed cellular debris constituted the medulla. 
Similarly, at 14 and 21 days after grafting virtually 
all medullary thymocytes were eliminated and the 
medullary area was shrunken to 5% of its normal size 
(Fig. 5.10). At 50 days regeneration of the medullary 
compartment was manifested by the formation of 
multiple small medullary areas in each thymic lobule 
(Fig, 5.11) that expanded and coalesced to form 
normal medullary compartments by 100 days (Fig. 5.12). 
The CyA treatment alone, in animals who received no 
cardiac allograft, caused a similar, although slightly 
less extensive, decrease in medullary thymocytes when 
examined at 3, 7, 14 and 21 days.
■
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FIGURE 5.9
m
Thymus of CyA-treated (LEW) recipient of (LEW x BN)F^ 
cardiac allograft at 3 days. A marked increase in most 
cells in the thymic cortex (C) is noted. xlOO
Thymus Histology
FIGURE 5.10
Thymus of CyA-treated (LEW) recipient of (LEW x BN)F^ 
cardiac allograft at 21 days is shown. Virtually all 
medullary thymocytes (M) were eliminated and the 
medullary area was shrunken to 5% of its normal size. 
x40
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FIGURE 5.11
Thymus of CyA-treated (LEW) recipient of (LEW x BN)F^ 
cardiac allograft at 50 days is shown. The medullary 
compartment is regenerating as manifested by the 
formation of multiple small medullary areas (M) in each
thymic lobule. x50
Thymus Histology
FIGURE 5.12
ë
: m m ^
Thymus of CyA-treated (LEW) recipient of (LEW x BN)F^ 
cardiac allograft at 100 days is shown. The medulla has 
been reconstituted (M). 
x50
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c) Cardiac Allografts
Acute rejection in untreated rats was accompanied by a 
progressive increase in graft weight (from 0.85 g at 
day 0 to 1.7 g at day 7) (Fig. 5.13). In CyA-treated 
rats cardiac grafts increase initially in weight to 
1.25 g at 3 days but return to normal weight (0.88 g) 
by 7 days. Normal graft weight was then maintained 
until a slow progressive weight increase occurred 
after 50 days. These weight ranges were small (Fig. 
5.14) .
These experiments have demonstrated that CyA treatment 
results in the marked reduction in size of the thymic 
medulla, the splenic PAS and the splenic MZ. Previous 
studies have suggested that T lymphocytes which arise 
originally in the bone marrow and migrate to the thymic 
medulla then migrate to the PAS and MZ areas 
(Goldschneider, 1976). Because helper and cytotoxic 
T lymphocytes may develop in the thymic medulla while 
suppressor T lymphocytes may originate in the thymic 
cortex (Small,1978), CyA may be predicted to favour 
suppressor cell function. , These morphological changes 
in the spleen and thymus of CyA-treated animals support 
the result of the earlier cell transfer studies 
suggesting the presence of suppressor cells in rats 
receiving a cardiac allograft and treated with CyA.
Cardiac Allograft Weights in Untreated Recipients
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DISCUSSION
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The ideal immunosuppressive regimen would be both 
potent and safe, i.e. it would be effective in the vast 
majority of treated patients and be associated with 
negligible morbidity and mortality. The fact that a 
significant number of organ grafts fail, due largely 
to uncontrollable rejection, and that there are very 
serious and sometimes fatal complications of 
conventional immunosuppressive therapy is a clear 
indication that current therapy is far from ideal. The 
major problem with the drugs currently in use is that 
their immunosuppressive effects are a by-product of a 
general toxic effect on cells, with the result that 
potency and safety oppose one another.
The rejection of tissue or organ allografts is the 
culmination of interconnected cellular and humoral 
events mediated by various lymphoid cell subgroups.
The lymphocyte populations, their function and their 
intricate inter-relationships occurring throughout the 
immune system are gradually becoming better defined. 
"Cytotoxic” cells are responsible for destroying the 
allograft and "helper" cells support the rejection 
process by promoting the activity of cell-mediated and 
humoral immunity. In addition, Gershon and 
colleagues (1972) demonstrated that lymphocytes can 
have a suppressive effect on the immune system. These 
suppressor cells can be defined as cells, usually
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subpopulations of lymphocytes, which suppress the 
reactivity of other lymphocytes. Although B cells 
(Gill and Liew, 1979) or macrophages (Anacle^io et al,
1979) may act as suppressor cells, the latter usually 
non-specifically, most suppressor cells have proved to 
be T lymphocytes as shown by the loss of suppressor 
activity after treatment of the cell population with 
anti-T lymphocyte antibodies and complement.
In many experimental models as well as in clinical 
transplantation the predominant strategies available 
to inhibit host activity against foreign tissues have 
been various immunosuppressive agents, the majority of 
which affect lymphocyte populations indiscriminately. 
Probably the highest degree of drug specificity 
possible would be for a drug to interact exclusively 
with proliferating T cells known to be vital for graft 
rejection i.e. cytotoxic and helper T cells. However, 
even if this was the case, it is important to note that 
such a drug may still be associated with problems 
since it would also suppress the immune response to 
invading pathogens. Recent evidence suggests that CyA 
has a selective action on lymphoid cells and may be the 
first of a new generation of drugs capable of 
selective immunoregulation.
In 1976 Borel demonstrated that CyA depressed immune 
reactions both in vivo and in vitro and prolonged skin 
graft survival in mice. This observation led to
.3.
studies of CyA in different species with a variety of 
organ transplants. The rejection of heterotopic heart 
allografts in rats was delayed by CyA (Kostakis et al, 
1977). CyA was more effective than azathioprine in 
prolonging dog renal grafts (Caine and White, 1977), 
renal allografts in rabbits (Green and Allison, 1978), 
orthotopic cardiac allografts in pigs (Caine et al, 
1978a) and dog pancreatic grafts (McMaster et al, 
1980).
One of the most important observations made in the 
small animal grafting experiments is that for many, 
although not all, of the organs transplanted e.g. 
heart, kidney and liver in the rat, a short course of 
CyA produces a very prolonged graft survival. This 
phenomenon suggests that CyA may suppress clones of 
responding cells or alter a balance between the T 
helper and T suppressor cells such that non­
responsiveness is induced. Du Toit and colleagues in 
1980 found however that canine renal and pancreatic 
allografts were invariably rejected 1 to 3 weeks after 
stopping CyA treatment 14, 21 or 100 days after 
transplantation, suggesting that clonal deletion is 
not a mechanism of action in the dog.
Following these early animal experiments a pilot study 
was begun using CyA in clinical organ grafting 
initially as the sole immunosuppressive agent (Caine 
et al, 1978b). This study involved 50 patients
receiving 56 cadaveric organ allografts, 45 kidneys, 6 
pancreases and 5 livers. The results were encouraging 
and numerous other, clinical investigations have 
subsequently been initiated. The initial concern that 
lymphomas would be common after the use of CyA has not 
been fulfilled.
Although its pharmacodynamics are not well understood 
certain information is available. Borel and colleague: 
in 1976 reported that CyA inhibited humoral immunity in 
rodents as measured by the reduction of plaque-forming 
cells and haemagglutinin titres. It also suppressed 
cell-mediated immunity in such models as skin graft 
rejection, graft versus host disease, delayed hyper­
sensitivity, skin reactions and experimental 
encephalomyelitis. Lymphocytes appear to be the 
primary target of CyA since granulocyte proliferation 
and macrophage function both appear to be unaffected by 
therapeutic doses (Borel et al, 1976; Borel and 
Weisinger, 1977; Paavonen and Hayry, 1980). In 
addition, it appears to act preferentially on T cells 
(Borel et al, 1976). Other early studies suggested 
that B cells in rats (Burckhardt and Guggenheim, 1979), 
and in humans (Gordon and Singer, 1979), were 
unaffected. However, more recently in the mouse,
Kunkl and Klaus (1980) have suggested that CyA affects 
a subpopulation of B cells and that these are as 
sensitive to CyA as are certain subpopulations of T 
cells,
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In studies on pig. cells (White et al, 1979) and human 
lymphocytes (Weisinger and Borel, 1979) CyA was shown 
to inhibit an early stage of T cell activation and in 
addition recent studies, using human lymphocytes, have 
suggested a selective inhibiting effect on T helper 
cells (Leapman et al, 1981).
By considering the model (Fig. 6.1) proposed by Wagner 
and his colleagues in 1980 more information of T cell 
activation is obtained and possible sites of CyA 
activity are postulated.
Using this model of T cell activation Bunjes and 
colleagues presented evidence showing that, in the 
mouse, CyA selectively impairs the release of 
Interleukin 2 (IL^) from activated T helper cells and 
that of Interleukin 1 (IL^) from macrophages, thus 
inhibiting the generation of cytotoxic T lymphocytes 
and T helper cells. These workers did not however 
test suppressor cell activity although suppressor cells 
are apparently spared by CyA in this model. This mode 
of action explains why CyA is so effective in blocking 
mitogen-activated as well as allo-antigen-activated 
proliferative T cell responses in vitro (White et al, 
1979; Horsburgh et al, 1980), Data from other in vitro 
investigations, using human lymphocytes, have suggested 
that CyA permits the generation of suppressor 
lymphocytes (Hess and Tutschka, 1980), Additional 
studies in vivo by Tutschka and colleagues in 1981
1
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FIGURE 6.1
Method of T~cell Activation
13 9
Ag
T-helpcr sub-population
Ag C yto toxic T-cell 
_ precursor
T helper 
cell
C ylo tox ic-T  cells
Interleukin 1 (IL^) is produced by macrophages on 
encountering’ the antigen (Ag). IL^ acts on a sub­
population of T' helper cells along with the antigen to 
evoke the production and release of Interleukin 2 (IL^) 
This in turn acts on antigen-primed T helper cells and 
cytotoxic T-cell precursors, inducing mitogenesis of 
these cells. helper cells enhance the activity of 
cytotoxic cells and B cell antibody production directed 
against the antigen.
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demonstrated suppressor cells in rats grafted with 
incompatible bone marrow and treated with CyA were able 
to prevent graft versus host disease. Thus it would 
appear from these experiments that CyA has a sparing 
effect on suppressor cells while inhibiting cytotoxic 
T lymphocyte generation in response to antigen.
In these present studies it has been shown that CyA is 
a potent immunosuppressive agent in the rat cardiac 
allograft model. Allografts in both combinations,
(LEW X WF)F^ to LEW and (LEW x  BN)F^ to LEW, function 
100 days without rejection episodes in consistently 
healthy recipients being given intramuscular CyA 
15 rag/kg/day for 7 days only, commencing immediately 
after transplantation. Allografts in untreated animals 
survived only 7 days + 1 day.
In some experimental (Borel et al, 1976) and clinical 
(Keown et al, 1981) situations CyA suppresses both 
humoral and cell-mediated immunity. However, in CyA- 
treated rats receiving renal allografts (Homan et al, 
1980a) and in recipients treated with a combination of 
CyA, antilymphocyte serum and enhancing antiserum 
(Homan et al, 1979; Homan et al, 1980b) antibody 
synthesis is diminished, although cell-mediated immune 
responses are only marginally suppressed. Homan and 
colleagues suggested that the suppression of the 
antibody response could be attributable to non­
reactivity in the helper T lymphocyte or B lymphocyte
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populations. A T helper effect seems more likely, both 
because CyA appears to act preferentially on T cells 
(Borel et al, 1976) and because T lymphocytes are more 
easily inactivated than B lymphocytes (Chiller et al, 
1971).
In the studies described in this thesis lymphocyte- 
mediated cytotoxicity mounted by lymphocytes from 
various host lymphoid compartments, including cells 
infiltrating the grafts themselves, was reduced after 
transplantation and treatment with CyA. In addition, 
anti-donor antibody activity as measured by complement- 
dependent cytotoxicity, antibody-dependent cell- 
mediated cytotoxicity and the reverse haemolytic 
plaque assay, was also diminished significantly when 
compared with control animals. Such suppression of 
cell-mediated and humoral immunity was noted 
throughout the 100 day period after transplantation.
Many of the experiments mentioned previously have 
proposed the sparing effect of CyA on suppressor cells 
and indeed the present cell transfer experiments would 
support this theory. In these investigations it has 
been demonstrated that CyA-treated rats bearing well- 
functioning cardiac allografts develop a population of 
lymphoid cells with suppressor activity exerted in 
vivo against donor allo-antigens, Thus, thymocytes 
from such animals can increase survival of test 
cardiac allografts following transfer into unmodified
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syngeneic animals. In the present experiments lymphoid 
cells transferred from grafted animals at any time after 
cessation of CyA treatment increased survival of test 
allografts significantly. Survival is not prolonged if 
cells are transferred during the 7 days of treatment.
The suppressor effect is fully sustained at least three 
months after transplantation by which time any 
remaining drug would have been metabolised. Such a 
state of specific unresponsiveness is not without 
precedent in organ graft systems: it has been noted 
that a similar result can be achieved in enhanced 
recipients of heart grafts (Tilney et al, 1978). Other 
investigators have also demonstrated prolonged test 
allograft survival following cell transfer but the 
immune responsiveness of the recipients was invariably 
diminished before transfer (Dorsch and Roser, 1977; 
Droege, 1975; Kilshaw and Brent, 1977). The work in 
this thesis shows the same phenomenon in recipients 
with normal immune systems prior to cell transfer.
#
Some authors (Caine et al, 1978b; White et al, 1979; 
Deeg et al, 1980) have suggested that CyA itself or a 
metabolite is the suppressive principle which can be 
removed by washing the cells. The findings in these 
present experiments are in variance with this concept 
as stripping the surfaces of the transferred cells 
with trypsin did not affect their suppressor activity. 
Additionally, the inability of cells from CyA-treated 
but ungrafted animals to prolong test graft survival
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also demonstrates that a continuing antigenic stimulus 
as well as effects of the drug are required for the 
development of suppressor cells.
These findings of cells with suppressor characteristics 
are supported by the results of the studies of dynamic 
responses of certain lymphoid tissues to the cardiac 
allograftso The medullary compartment of the thymus 
and the splenic peri-arterial sheath and marginal zone 
areas were strikingly reduced in size (by 97, 50 and 
67% respectively) 1 to 2 weeks after the completion of 
CyA treatment. The elimination of medullary 
thymocytes with partial preservation of cortical 
thymocytes in the 2 weeks following only 7 days of CyA 
treatment was as consistent as it was dramatic. This 
selective effect of CyA on cells in the medulla of the 
rat thymus is unique. Other commonly used chemical 
immunosuppressants, such as 6-mercaptopurine, 
cyclophosphamide and prednisolone, preferentially affect 
cortical thymocytes (Miller and Cole, 1967; Weissman, 
1973). Antilymphocyte serum, which also depletes T 
lymphocytes in the splenic peri-arterial sheath, has 
little or no effect of the thymus (Taub and Lance,
1968).
Studies using the rat masked thymocyte antigen suggest 
that T lymphocytes in these compartments may arise 
originally in bone marrow and migrate first to the 
thymic medulla and then to the splenic peri-arterial
_______
sheath via the marginal zones (Goldschneider, 1976; 
Nieuwenhuis and Ford, 1976), A second line of T 
lymphocytes bearing the rat bone marrow lymphocyte 
antigen may migrate first to the thymic cortex and 
then to the splenic red pulp. These rat bone marrow 
antigen-bearing T lymphocytes may be less susceptible 
to CyA as the thymic cortex and the splenic red pulp 
were only reduced in size by 50% and 10% respectively. 
Because helper and cytotoxic T lymphocytes may develop 
in the thymic medulla while suppressor T lymphocytes 
may originate in the thymic cortex (Small, 1978;
Durkin et al, 1978) CyA may be predicted to favour 
suppressor cell function.
The antigenic specificity of transferrable 
unresponsiveness using cells from LEW animals bearing 
(LEW X BN)F^ and (LEW x WF)F^ donor allografts was 
striking. These animals were chosen because they are 
incompatible for all known major histocompatibility 
antigens. The survival of test (LEW x WF)F^ cardiac 
allografts was prolonged to 13 + 2 days after 
thymocyte transfer from CyA-treated (LEW) recipients 
of (LEW X WF)F^ heart grafts 14 days after 
transplantation. However, no prolongation was noted 
when thymocytes from CyA-treated (LEW) recipients of 
(LEW X BN)F^ cardiac allografts were transferred at 
14 days into unmodified (LEW) recipients of (LEW x WF)F. 
test grafts (MST 2 8D = 6 + 1 day). Similarly 
(LEW X BN)F^ test grafts in (LEW) recipients survived
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for only 6 ^ 1 day after transfer of thymocytes from 
CyA-treated animals bearing (LEW x WF)F^ cardiac 
allografts. Hence the specificity of unresponsiveness 
to the original donor and not a third party animal was 
demonstrated„
Such striking specificity was also demonstrated in 
vitro, where reactivity by lymphocytes from CyA-treated, 
grafted rats in the mixed lymphocyte response was 
consistently suppressed against donor cells but no 
suppression of proliferation was noted against third 
party cells. However, as in the in vivo cell transfer 
experiments themselves, antigen-specific suppression 
occurred only several days following cessation of the 
drug.
Antigen-specific suppression has been suggested by 
Homan et al (1979) in studies of CyA-treated rats 
bearing renal allografts. These workers found that 
third party kidneys were rejected rapidly although the 
CyA-treated hosts lost almost completely their ability 
to mount an antibody response to these third party 
grafts. Green et al (1979) also supported antigen- 
specific suppression in studies of renal allografted 
rabbits, although Dunn et al (1978) in investigations 
into the effect of the drug in kidney grafts in outbred 
rabbits demonstrated powerful but totally non-specific 
immunosuppressive activity. White and his colleagues 
in 1980, using rat cardiac allografts followed by donor
#
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or third party skin grafts at a later date, 
demonstrated that during CyA treatment and during the 
few days following cessation of treatment there was 
non-specific unresponsiveness to the skin grafts, 
whereas two weeks after stopping CyA administration 
specificity of response was shown.
The emergence of antigen-specific suppressor cells is 
not unique to CyA treatment. Dossetor and colleagues 
in 1981 studying 8 patients with renal transplants, 
receiving steroids and azathioprine, demonstrated that 
suppressor cells were not present in recipient blood 
before transplantation but that they were well 
established as early as 2 to 3 weeks after 
transplantation and were donor-specific. In this 
study the presence of these donor-specific suppressor 
cells was not however necessarily associated with a 
good clinical course. Jayavant and colleagues (1979) 
demonstrated, however, a significant correlation 
between a functioning, non-rejecting allograft and an 
allograft recipient's suppressor cell activity.
Suppressor cells have also been demonstrated with other 
immunosuppressive regimes, Askenase and colleagues in 
1975 studying cyclophosphamide-treated mice, immunised 
with sheep red blood cells, suggested that suppressor 
cells are present during immunosuppressive treatment.
In addition, it has also been shown from several 
laboratories that animals treated with antilymphocyte
serum possess suppressor T cells whereas comparable 
normal serum controls do not (Kelshaw et al, 197 5;
Wood and Monaco, 1979; Rudnicka, 1980). Thomas and 
fellow workers (1983) demonstrated that rabbit anti­
thymocyte globulin, by inducing non-specific suppressor 
cells in the recipients, prolonged the survival of 
skin allografts in rhesus monkeys. Using total 
lymphoid irradiation when studying bone marrow 
grafting in mice (Slavin et al, 1979) and kidney 
allografts in baboons (Smit et al, 1981), suppressor 
cells have also been demonstrated.
Concluding Comments
The aims of the studies described in this thesis 
have been fulfilled. Cyclosporin A has been shown 
to be a very potent immunosuppressive agent in the 
rat cardiac allograft model. Both the humoral and 
cell-mediated components of the immune response 
are markedly suppressed. It has also been shown 
that antigen-specific suppressor cells emerge 
following the cessation of Cyclosporin A treatment.
It is suspected that these suppressor cells act by 
abrogating or overriding the function of allo-specific 
helper T cells necessary for initiating 
differentiation of cytotoxic T lymphocytes and 
antibody-producing B cells.
'3t:
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The Future
The results of our experimental findings with CyA in 
the rat do not necessarily apply to other species. 
Although CyA is a powerful immunosuppressant in larger 
species, Du Toit and colleagues found that a short 
course of the drug failed to produce indefinite 
survival of kidney and pancreatic allografts in the dog. 
In the human, continuous CyA treatment is used to 
maintain organ graft survival. In these larger species, 
after many months of treatment, would suppressor cells 
emerge to allow the drug to he discontinued without 
additional treatment? If so, at what time could CyA be 
stopped without organ rejection? Would the dose of CyA 
need to be "tailed off"?
At present CyA is used by many transplant centres 
throughout the world. Some centres are extremely 
enthusiastic about its use (Caine et al, 1979; Starzl 
et al, 1981) whereas the experiences of the Royal Free 
Hospital, London (Sweny et al, 1981) and the Peter Bent 
Brigham Hospital, Boston (Carpenter et al, 1981) have 
been disappointing. It remains to be seen whether it 
will be more appropriate to use CyA alone, as Caine is 
doing, or CyA together with prednisolone in low dosage, 
as advocated by Starzl. Perhaps CyA and azathioprine 
would be a better combination?
II
The ideal immunosuppressive regimen would be without
side-effects. The initial concern, during the early 
clinical use of CyA, about the development of 
lymphomas (Caine et al, 1978b) has proved unfounded. 
Indeed, in the light of subsequent experience it is 
clear that the risk of developing a lymphoma is much 
the same in patients treated with CyA as in those 
treated with azathioprine, However, nephrotoxicity 
(Caine et al, 1979) and hepatotoxicity (Starzl et al,
1980) remain two toxic side-effects of the drug.
There remain many questions to be answered about CyA. 
It is a drug, however, that has made a significant 
advance in the search for the ideal immunosuppressant 
and it is probable that its full potential has yet to 
be realised.
14:;
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